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A rapid increase in Alzheimer’s disease (AD) patients is expected over the next 30 
years. Accordingly, there is a critical need for early-stage AD detection methods that can 
enable professionals to treat the disease adequately. The present study considers the ability of 
episodic-memory measures to predict mild cognitive impairment (MCI) to AD conversion 
and thus, detect early-stage AD. Using a binary logistic regression, episodic-memory tests 
were compared to each other and to prominent neuroimaging methods in MCI converter 
(MCI participants who developed AD) and MCI non-converter groups (MCI participants who 
did not develop AD). Standard tests for AD (e.g., MMSE) were also compared to specific 
episodic-memory tests—using a principal component analysis—to test if standard tests can 
measure episodic memory. Our study acquired all data from the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) and tested participants over four years. Our results indicate 
that individual episodic-memory measures could predict MCI to AD conversion better than 
episodic memory, neuroimaging, and mixed models. We theorised that mixed models were 
worse than individual tests, as mixed episodic-memory models increase multicollinearity and 
neuroimaging measures had poor accuracy. Specifically, the most accurate predictors were 
the ADNI memory score in year one (56.4%), the RAVLT percent forgetting measure in year 
two (71.7%), and the logical memory test in years three (76.9%) and four (77.2%). Our 
results also indicated that standard tests could be used to measure episodic memory. In 
conclusion, our study highlighted the ability of episodic-memory tests to predict disease 





• Alzheimer’s Disease = AD 
• Mild Cognitive Impairment = MCI 
• Amnestic MCI= aMCI 
• Non-Amnestic MCI= naMCI 
• Alzheimer’s Disease Neuroimaging Initiative = ADNI 
• Amyloid Beta = Aβ 
• Apolipoprotein E4 = APOE4 
• Magnetic Resonance Imaging = MRI 
• Positron Emission Tomography = PET 
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Chapter One: Background and Literature Review 
 
1.1 Introduction 
Alzheimer’s disease (AD) is the second leading cause of death in Australia and, 
consequentially, is one of the greatest medical threats of our time (Australian Bureau of 
Statistics, 2017). Specifically, AD is the most common form of dementia, which, in turn, 
currently affects 436,000 Australians (Australian Bureau of Statistics, 2017; Dementia 
Australia, 2018). Worryingly, dementia diagnoses are expected to increase drastically from 
50 million to 132 million global patients in the next 30 years (Alzheimer’s Disease 
International, 2019). The rapid increase in AD patients is problematic, as the cause of AD is 
currently unknown (Alzheimer’s Association, 2018). Furthermore, current AD diagnoses 
occur at a later stage of the disease, when neurological damage is presumed to be irreversible 
and most medications are largely ineffective (Kalat, 2018, p. 206). Accordingly, current 
symptomatic treatments such as cholinesterase inhibitors and aged care can mostly treat 
physical and cognitive decline (e.g., memory and motor function loss) but cannot reverse or 
prevent the disease (Edvardsson, Winblad, & Sandman, 2008; Tan et al., 2014). Clearly, there 
is a need for significant innovations in AD diagnosis and treatment to overcome what is 
expected to be a global epidemic. 
Specifically, innovations in early-stage AD diagnosis are required to adequately treat 
and understand disease mechanisms. Research suggests that current diagnostic methods, such 
as standard paper-and-pencil tests (e.g., Clinical Dementia Rating Scale), cannot reliably 
diagnose the early stages of AD. Moreover, diagnostic methods which could potentially 
categorise early-stage AD (e.g., MRI) are often unavailable to patients as they are vastly 
unaffordable and inaccessible. Alzheimer’s Disease must be diagnosed as quickly as possible, 
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as early-stage treatment can reduce the rate of neurodegeneration and prolong the onset of 
severe cognitive decline (Chu, 2012). Furthermore, early-stage AD detection enables 
researchers to examine the onset of the disease longitudinally and, therefore, understand 
disease pathogenesis and progression (Reiman et al., 2012). Accordingly, innovations in 
early-stage AD diagnosis could lead to the detection of the disease at a significantly 
manageable and reversible stage (Frisoni et al., 2017). The Alzheimer’s Association predicts 
that innovations in early-stage AD diagnostic methods could save the US alone $7.9 trillion 
in future treatment costs (Alzheimer’s Association, 2018). Clearly, there is a critical need for 
new AD diagnostic methods which can detect the early stages of the disease. 
Thus, this study investigates methods of predicting early-stage AD progression. 
Specifically, we use longitudinal data from episodic-memory tests to predict AD 
development in participants with MCI (an interim disorder which commonly converts to 
AD). Cognitive tests are used to predict disease conversion, as episodic-memory decline is 
one of the first symptoms of early-stage AD (Perry, Watson, & Hodges, 2000). Moreover, we 
examine the predictive ability of episodic-memory tests in comparison to magnetic-
resonance-imaging (MRI) measures of brain volume, which are commonly used to predict 
early-stage AD. Accordingly, we seek to predict early-stage AD and to evaluate the 
predictive ability of episodic-memory tests compared to the currently standard neuroimaging 
measures. By predicting early-stage AD and evaluating current disease measures, this study 
hopes to contribute to the formulation of better diagnostic measures and, thus, improve 





1.2 Theories of Alzheimer’s Disease Pathogenesis 
Many aspects of AD, such as the development and progression of the disease (i.e., 
pathogenesis), are not fully understood. Accordingly, theories such as the amyloid cascade 
and cholinergic hypotheses provide great insight into AD pathogenesis and can be used to 
inform early-stage AD diagnostic research. 
The amyloid cascade hypothesis suggests that AD development is related to the 
aggregation and formulation of neurotoxic matter known as plaques and tangles (Bloom, 
2014). Specifically, high concentrations of the peptide amyloid beta (Aβ) result in the 
formulation of plaques and the protein tau in neurofibrillary tangles. Why Aβ and tau 
aggregate to the point of neurotoxicity is unknown; however, both Aβ and tau aggregation 
correlate with AD progression (Murphy & LeVine, 2010). Research has shown that high 
concentrations of Aβ interrupt the dendritic function and synaptic ability of neurons 
(Yankner, Duffy, & Kirschner, 1990). Accordingly, the loss of synaptic ability leads to 
communication breakdowns, neuronal failure, the formulation of further senile plaques, and 
thus cascading neurodegeneration. In addition, research has shown that the gene 
apolipoprotein E (APOE) assists in the regulation of Aβ in the brain (Michaelson, 2014). The 
apolipoprotein E4 (APOE4) allele is subsequently a risk factor for AD development, as the 
APOE gene variant lacks the ability to sufficiently clear Aβ build up in the brain; however, it 
is essential to note that APOE4 is only a risk factor for AD, as the gene has no known causal 
relation to the disease (Uddin et al., 2019). 
Tau is a protein found in the axons of neurons. Tau is pivotal in maintaining cell 
structure and integrity (Weingarten, Lockwood, Hwo, & Kirschner, 1975). When senile 
plaques compromise the brain, Aβ modulates tau (in a process known as 
hyperphosphorylation), thereby causing the protein to spread from the axon to the wider 
neuron (Iqbal, Liu, Gong, & Grundke-Iqbal, 2010). Hyperphosphorylated tau forms into 
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clumps known as neurofibrillary tangles which impale neurons, thus compromising the 
structural integrity of the cell and causing further neurodegeneration. Accordingly, the 
assaults of both Aβ and tau are both malicious and meticulous, with tau compromising 
neurons internally and Aβ dismantling them externally. The amyloid cascade hypothesis 
states that Aβ and tau derived neurodegeneration starts in the hippocampus and progressively 
expands into the wider medial temporal lobe (MLT) and cortex (El Haj, Antoine, Amouyel, 
et al., 2016). Research shows that spreading neurodegeneration is correlated with symptoms 
of AD progression. For example, neurodegeneration in the cerebral cortex correlates with 
increased aggression and the loss of fine motor skills in AD (Kalat, 2018, p. 204). 
Accordingly, the amyloid cascade hypothesis is the current theoretical basis for the majority 
of AD progression and biomarker research; however, one common critique of the theory is 
that the hypothesis lacks specific information regarding the manifestation of higher-order 
deficits such as cognitive decline in AD. 
The cholinergic hypothesis originally stated that the depletion and dysfunction of the 
neurotransmitter acetylcholine causes cognitive decline in AD (Bartus, Dean, Beer, & Lippa, 
1982). However, modern iterations of the theory consider cholinergic decline to be a risk 
factor or contributory process towards cognitive decline in AD (Craig, Hong, & McDonald, 
2011). The cholinergic system of the brain is instrumental in managing attention, 
neuroplasticity, and complex cognitive processes such as memory (Teipel, Grinberg, Hampel, 
& Heinsen, 2009). Accordingly, there is a clear link between the higher-order symptoms of 
AD and tasks which involve the cholinergic system. For example, neurodegeneration in the 
basal forebrain is related to the loss of acetylcholinic neurons and memory function in AD 
(Ferreira-Vieira, Guimaraes, Silva, & Ribeiro, 2016; Francis, Palmer, Snape, & Wilcock, 
1999). In healthy aging, it is typical for cholinergic neurons to degenerate slowly (Davidson 
& Winocur, 2010); however, modern iterations of the cholinergic hypothesis state that in AD, 
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cholinergic decline is drastically increased by senile plaques and neurofibrillary tangles 
(Craig et al., 2011). Accordingly, the cholinergic hypothesis provides evidence to suggest that 
higher-order decline in AD occurs beyond the mechanisms of the amyloid cascade 
hypothesis. 
It is essential to note that the cholinergic hypothesis, while providing valuable 
information on cognitive decline, does not provide as cohesive an explanation of AD as once 
thought. Cholinergic decline is only seen as a risk factor for AD, as the theory lacks 
widespread experimental support (Terry & Buccafusco, 2003). However, to date, 
cholinesterase inhibitors are the only medications which viably treat and delay cognitive 
decline in AD. Accordingly, theories such as the amyloid cascade hypothesis regard 
cholinergic decline as a symptom of neurodegeneration in AD (Armstrong, 2013). 
Nonetheless, while the cholinergic hypothesis is lacking, the theory does highlight the need 
for a deeper understanding of AD progression and cognitive decline.  
Moreover, while current theories such as the amyloid cascade hypothesis provide 
insight into AD, they do not sufficiently explain the disease (e.g., cognitive decline). For 
example, biological markers of AD which are centric to current theories (e.g., APOE4 and 
Aβ) are not strong predictors of early-stage AD (Liu, Kanekiyo, Xu, & Bu, 2013). 
Accordingly, there is a gap in the literature concerning AD markers which can both detect the 
early stages of the disease and inform theories of pathogenesis and cognitive decline in AD. 
Clearly, there is a critical need for further research which can inform current theories and 
early-stage AD detection methods. Thus, by investigating cognitive decline (specifically 
episodic-memory decline), this research project seeks to inform gaps in early-stage AD 
progression theories and predict early-stage AD.  
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1.3 Early-Stage Alzheimer’s Disease Research 
1.3.1 The Alzheimer’s Disease Continuum 
Early-stage AD research often aims to predict disease development and observe the 
progression of pathological markers (e.g., Aβ aggregation). In turn, these disease predictors 
and markers inform early-stage AD diagnosis strategies and potential treatment areas. 
Researchers commonly predict early-stage AD and identify pathological markers by 
longitudinally studying precursor disorders which transition to AD. Specifically, the 
Alzheimer’s Association and the National Institute on Aging recognise AD as a continuum 
with three different stages known as preclinical AD, MCI, and AD dementia (Jack et al., 
2011). Accordingly, preclinical AD and MCI are often used to study early-stage AD. 
Preclinical AD is the initial stage of AD development and is an asymptomatic state which can 
last decades before transitioning to MCI or AD (Dubois et al., 2016). Due to the nature of 
preclinical AD, MCI is preferred in early-stage AD research as MCI is easier to predict, 
recognise, and study. 
MCI refers to the nondemented impairment of at least one cognitive ability, such as 
language or memory (Csukly et al., 2016). It is important to note that these impairments are 
not debilitating in MCI. Debilitating impairments indicate another disorder such as dementia. 
Moreover, MCI is not exclusive to AD development, yet MCI does share many 
characteristics with AD and reliably converts to the disease (Albert et al., 2011). Specifically, 
individuals with MCI convert to AD at a rate of 10-15% while only 2-4% of the general 
population progress to AD (Roberts et al., 2008). Two types of MCI are characterised by the 
specific domain impaired. If memory is impaired, the disorder is known as amnestic MCI 
(aMCI). If any other cognitive domain is impaired (e.g., language), the disorder is known as 
non-amnestic MCI (naMCI) (Tannenbaum, Paquette, Hilmer, Holroyd-Leduc, & Carnahan, 
2012). Accordingly, the classification of MCI is important, as aMCI reliably converts to AD 
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while naMCI converts to other disorders such as Parkinson’s Disease and non-Alzheimer’s 
dementia (Ferman et al., 2013; Goldman, Weis, Stebbins, Bernard, & Goetz, 2012). 
Consequently, most if not all of early-stage AD research investigates aMCI participants.  
1.3.2 Overcoming Barriers in AD Research  
Clearly, understanding aMCI and memory loss is essential when investigating early-
stage AD. However, studying AD and MCI participants can be incredibly complicated.  
AD and MCI research is incredibly complex and is often limited by three main 
factors. First, the logistical complexity of organising and recruiting neurological populations 
(e.g., individuals with dementia) can limit MCI and AD participant counts. For example, 
neurological participants, such as participants with AD, are likely to drop out of longitudinal 
studies as the symptoms of their disease worsen (Watson, Ryan, Silverberg, Cahan, & 
Bernard, 2014). Second, high monetary and administrative costs restrict the use of AD 
detection methods. For example, MRI technology can measure neurodegeneration with high 
accuracy, yet the device is incredibly expensive to use and hard to access (Stites, Milne, & 
Karlawish, 2018). Finally, the resources required to study AD progression and MCI 
conversion longitudinally are immense and beyond the scope of some labs. In any case, the 
resources required to study early-stage AD are beyond the scope of this study. However, 
these temporal, logistical and recruitment barriers to AD research can sometimes be 
overcome through joint research projects such as the Alzheimer’s Disease Neuroimaging 
Initiative (ADNI). 
ADNI is the largest and most commonly used research database in the AD literature. 
Most importantly, for researchers, ADNI provides complex longitudinal data with numerous 
clinical and experimental measures of MCI and AD participants. As an organisation, ADNI 
seeks to detect and observe AD progression using disease biomarkers. For more information 
see the Alzheimer’s Disease Neuroimaging Initiative (2017a). Specifically, ADNI collects 
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neuroimaging, traditional biomarker, neuropsychological, and demographic measures in a 
cohort of control (neurologically healthy), MCI, and AD participants. For more information 
see the Alzheimer’s Disease Neuroimaging Initiative (2017b). Most importantly, for this 
project, ADNI operates on a policy of information sharing which enables any study with an 
institutional ethics approval to use their data for research. Accordingly, researchers can study 
topics such as early-stage AD by using the ADNI database while overcoming the logistical, 
temporal and economic limitations common to AD research. Thus, this project uses the 
ADNI database to predict MCI to AD conversion and, therefore, to detect early-stage AD. 
1.3.3 Common Methods of Early-Stage AD Research 
Alzheimer’s disease research is commonly categorised into the three fields of 
neuroimaging, biomarker, and neuropsychological research. In the case of ADNI, each of 
these fields seeks to investigate and predict AD progression using pathological markers or 
measures. Importantly, ADNI chooses its markers and methods according to the surrounding 
literature; however, the popularity and accessibility of the ADNI database also significantly 
affect the popularity of some measures and methods. 
Biomarker research 
Traditional biomarker research assesses biochemical changes in the brain which are 
associated with AD. For example, AD biomarker research commonly investigates genes, 
proteins, and peptides such as APOE4, tau, Aβ42, and presenilin-1 (Natelson Love et al., 
2017; Sharma & Singh, 2016). Unlike neuroimaging and neuropsychological methods, 
traditional biomarkers require the extraction of biological material, which can often involve 
invasive procedures (e.g., lumbar punctures). For example, ADNI collects blood, cerebral 
spinal fluid (CSF), and urine samples to study plasma, enzymes, proteins, amino acids, and 
genes which are biomarkers for AD. Overall, biomarkers provide great insight into the 
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progression and symptoms of AD; however, traditional biomarkers are weak predictors of 
early-stage AD compared to neuroimaging and neuropsychological measures (Cui et al., 
2011). Research has shown that traditional biomarkers cannot strongly predict and detect the 
early stages of AD, as they often rely on symptomatic measures and risk factors (Liu et al., 
2013; Yip, Brayne, Easton, & Rubinsztein, 2002). Consequently, traditional biomarkers are 
only useful predictors of early-stage AD when they form parts of a mixed predictive model 
(e.g., combined with neuroimaging measures) (Vemuri et al., 2009). Moreover, biomarkers 
also find little use in clinical diagnoses, as procedures are often uncomfortable or invasive 
and biomarker samples requiring lab processing. Comparatively, neuropsychological pen-
and-paper tests are often preferred because they require no adverse procedures and can be 
conducted quickly on site. 
Neuroimaging research 
Neuroimaging research commonly uses electromagnetic signals to noninvasively 
measure neurodegeneration and metabolic changes in AD (e.g., MRI measures of 
hippocampal atrophy). Neuroimaging research is, in part, a form of biomarker research but is 
often separated from traditional biomarkers due to the size and unique methodology of the 
field. Magnetic resonance imaging (MRI) and positron emission tomography (PET) are the 
most commonly used methods in neuroimaging research. In ADNI, MRI measures broadly 
assess brain atrophy, volume, and neuron connectivity while PET measures assess brain 
metabolism and Aβ pathology (Davatzikos, Bhatt, Shaw, Batmanghelich, & Trojanowski, 
2011; Ewers et al., 2014; Landau et al., 2012). Neuroimaging technology is highly accurate 
when used to predict early-stage AD, especially when MRI measures of brain volume and 
atrophy are used. For example, MRI measures of hippocampal atrophy and entorhinal volume 
are some of the best predictors of MCI to AD conversion and, therefore, of early-stage AD 
(Brueggen et al., 2015; Tapiola et al., 2008; Velayudhan et al., 2013). Furthermore, 
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neuroimaging measures provide in-depth analyses of neuronal health and brain connectivity 
in AD (Cai et al., 2015).  
Clearly, neuroimaging methods are at the forefront of AD research; however, these 
measures have little application to clinical practise as the technology has a high temporal, 
monetary, and logistical cost. Accordingly, the Alzheimer’s Association and the National 
Institute on Aging suggest that biomarkers (including neuroimaging methods) can inform 
diagnoses when possible but cannot be used to diagnose the disease without further 
technological development (Jack et al., 2011). 
Neuropsychological research 
Neuropsychological research focuses primarily on measuring cognitive and functional 
ability (e.g., motor skills and memory). Accordingly, pen-and-paper tests are commonly used 
to diagnose AD and to monitor at-risk patients (e.g., MCI patients). For example, ADNI 
currently uses 11 cognitive, and 10 functional and behavioural tests to monitor all AD, MCI 
and control participants. In neuropsychology, cognitive tests can be further divided into three 
categories depending on the nature and use of the specific test (Brown, 2015). In AD 
research, cognitive tests can broadly be categorised as the following: Short questionnaires 
used for screening AD (e.g., abbreviated mental test), highly specific tests used to 
discriminate between similar diseases such as vascular dementia and AD (e.g., the clock-
drawing test), and general multi-domain tests commonly used for AD diagnosis (e.g., the 
Mini-mental-state Exam) (Brown, 2015; Kato et al., 2013; Swain, O’Brien, & Nightingale, 
1999).  
General multi-domain tests are the most commonly used neuropsychological 
measures in both clinical practice and research. Accordingly, these general multi-domain 
tests are often referred to as standard tests. Standard tests boast a high accuracy in AD 
research and are the current standard for clinically diagnosing AD. Standard tests are widely 
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used throughout the literature, as they are easily administrable and affordable in comparison 
to other measures (e.g., MRI); however, standard tests lack the ability to diagnose early-stage 
AD and are prone to misdiagnosing forms of dementia (e.g., diagnosing vascular dementia as 
AD) (Arevalo-Rodriguez et al., 2015; Bak et al., 2005; Larner, 2019). Accordingly, early-
stage AD research does not commonly focus on cognitive predictors of early disease 
development or MCI conversion. Nonetheless, the literature has suggested that highly 
specific tests which target the early cognitive symptoms of AD (e.g., episodic-memory 
decline) could be used to diagnose the early stages of the disease (Bastin & Salmon, 2014; 
Brown, 2015). However, due to the dominance of standard tests and preference for 
neuroimaging and biomarker measures in the literature, research is lacking on the predictive 
ability of specific cognitive tests in early-stage AD research. Thus, further research is 
required to validate the predictive ability of specific cognitive tests in early-stage AD 
research. 
Clearly, neuroimaging, biomarker, and neuropsychological research have unique 
strengths which, with further innovation, could enable each field to detect early-stage AD. 
However, each field also has weaknesses which currently limit early-stage AD prediction and 
diagnosis. Accordingly, there is a need for neuroimaging and biomarker research to become 
more clinically reliable and accessible. Moreover, neuropsychological and biomarker 
research must overcome flaws in accuracy, reliability, and validity to warrant use in early-
stage AD diagnosis. Thus, this study investigates the ability of specific cognitive tests to 
predict MCI to AD conversion and, therefore, early-stage AD. This project assesses cognitive 
tests over other measures (e.g., neuroimaging) for the following reasons: A) studying 
cognitive tests enables us to address the theoretical gaps concerning the development of 
cognitive decline in early-stage AD, B) cognitive tests are standard measures of AD yet lack 
research concerning early-stage AD, and C) specific cognitive tests could overcome some of 
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the limitations of general tests for AD diagnosis (e.g., poor early-stage AD detection). 
Accordingly, this project uses episodic-memory tests to predict MCI to AD conversion in the 
ADNI database and, thus, detect early-stage AD.  
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1.4 Episodic Memory in Alzheimer’s Disease Research 
1.4.1 Episodic Memory and Decline 
Episodic-memory decline is one of the first indicators of AD progression and, thus, is 
an optimal candidate for early-stage AD detection and prediction. Episodic memory is an 
archival form of memory that encodes events with temporal and positional details to create 
complex situational memories (Tulving, 1972, 1985, 2002). Episodic memory is an 
incredibly complex form of memory; consequentially, our understanding of it remains mostly 
theoretical. Accordingly, current theory states that episodic memory function occurs using 
multiple neurological structures and systems; this is the component process model of episodic 
memory (Morris Moscovitch, Cabeza, Winocur, & Nadel, 2016, p. 2). It is widely agreed that 
episodic-memory processes occur predominantly in the medial temporal lobe (MTL) and 
cortex. Moreover, the component process model regards the hippocampus as the centrepiece 
of episodic-memory processing (Eichenbaum, 2017). 
The component process model states that the hippocampus is a hub that combines and 
translates information from across the brain to construct episodic memories. It is not clear 
what specific relationships and executive processes directly result in the formulation of 
episodic memory; however, theory suggests that sensory, object, context, temporal, spatial, 
and emotional information are all incorporated in the hippocampus to develop an episodic-
memory engram (Barker et al., 2017; Morris Moscovitch et al., 2016). Furthermore, this 
multitude of information is previously processed in and then received from the MTL and 
neocortex (M. Moscovitch, 1992). Because episodic memories form through the complex 
integration of multiple systems, research suggests that the brain uses electronic signals known 
as neural oscillations (also known as brain waves) to coordinate memory formation and 
recollection (Nyhus & Curran, 2010). Accordingly, electroencephalographic studies have 
observed theta-wave neural oscillations that are indicative of coordinated episodic memory 
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function (Hot et al., 2011). However, the structural complexity of the episodic memory 
system and its reliance on complex forms of communication also makes episodic memory a 
prime target for decline in AD. 
It is, therefore, no coincidence that episodic-memory decline is one of the first 
symptoms of early-stage AD, as both amyloid cascade and neurodegeneration are theorised to 
start in the hippocampus. Thus, the hippocampal system is pivotal to both episodic memory 
function and neurodegeneration in AD (El Haj, Antoine, Nandrino, & Kapogiannis, 2016). 
Accordingly, in AD, episodic-memory decline is theorised to occur because of 
communication breakdowns in neural oscillations due to interference from senile plaques and 
neurofibrillary tangles. Moreover, episodic-memory decline is also theorised to occur because 
of neurodegeneration in the MTL (El Haj, Antoine, Amouyel, et al., 2016; El Haj, Antoine, 
Nandrino, et al., 2016; Morris Moscovitch et al., 2016).  
As amyloid and neurodegenerative processes are poorly understood in AD, the 
pathogenesis and progression of episodic-memory decline also remain enigmatic. 
Contemporary theories of episodic memory focus more on the structures that decay than on 
the causes and progression of memory decline. However, with further research, contemporary 
theories of episodic-memory decline (e.g., the component process model) could address some 
of the theoretical gaps in the amyloid cascade hypothesis such as the onset of cognitive 
decline. If episodic-memory decline can be further understood, researchers can use it as a tool 
to predict and detect early-stage AD. Thus, this study seeks to predict early-stage AD and to 
understand episodic memory using the ADNI database. 
1.4.2 Episodic-Memory Tests in ADNI 
ADNI collects a vast amount of neuropsychological information for research through 
cognitive and psychological tests. ADNI uses 11 cognitive tests. The Logical Memory Test 
(LMT) and Rey Auditory Verbal Learning Test (RAVLT) are used to measure episodic 
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memory (Alzheimer’s Disease Neuroimaging Initiative, 2016, p. 21). The LMT is a revised 
form of the Weschler Memory Scale, which assesses episodic memory formulation and 
recollection using a short story (Abikoff et al., 1987). Similarly, the RAVLT assesses 
episodic memory by using a list-learning strategy that measures delayed word recall (Vakil & 
Blachstein, 1993). Evidence also suggests that the cognitive variant of the Alzheimer’s 
Disease Assessment Scale (ADAS-cog) and the Mini-mental-state Exam (MMSE) can predict 
episodic memory performance even though they do not explicitly assess episodic memory 
(Crane et al., 2012; Gomar et al., 2011). The MMSE and ADAS-cog are argued to test 
episodic memory, as they incorporate list learning and recall tasks. Some studies have argued 
that a combined total episodic-memory score from all the tests listed above best predicts AD 
(Seo, Choo, & Alzheimer’s Disease Neuroimaging Initiative, 2016); however, to our 
knowledge, no study has comprehensively assessed all episodic-memory measures in the 
ADNI database. All past and present ADNI data collection has incorporated the 11 tests, yet 
only a small literature examines episodic memory performance in the initiative’s cohort. 
Most of the ADNI studies that investigate episodic memory use the RAVLT alone as 
a measure of episodic memory. Only using the RAVLT could be problematic, as the accuracy 
and ability of most, if not all, episodic-memory tests are not fully understood in early-stage 
AD research. Moreover, many tests seek to quantify and measure constructs of episodic 
memory; however, there is no single, all-encompassing episodic-memory test (Cheke & 
Clayton, 2015; Humphreys, Smith, Pachana, Tehan, & Byrne, 2010). A study by Cheke and 
Clayton (2013) examined multiple episodic-memory tests and found that no single test fully 
measured the construct of episodic memory. Variations in memory tests are understandable, 
as episodic memory is an incredibly complex mental process for which no cohesive 
understanding appears in the literature (Tulving, 2002). Accordingly, cognitive tests are both 
limited by our understanding of episodic memory and by their ability to measure the 
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construct of episodic memory wholly and directly. Therefore, relying on a single episodic-
memory test such as the RAVLT may not wholly and directly measure episodic memory 
compared to a battery of tests, as suggested by Seo et al. (2016). The ADNI database has also 
used two versions of the RAVLT throughout the initiative's history. Evidence suggests that a 
difficulty is encountered in changing between RAVLT versions (Crane et al., 2012). The 
difficulty is confounding to studies that use only the RAVLT and do not control for variation 
differences when longitudinally assessing participants across ADNI cohorts. Accordingly, 
there is a critical need to comprehensively examine and understand episodic-memory 
measures in the ADNI database so that future research can use cognitive measures to their 
full potential. Moreover, there is a need to critically examine the ability of all ADNI episodic-
memory measures to predict early-stage AD. 
1.4.3 Episodic-Memory Research 
The ADNI episodic-memory literature is relatively small compared to other 
prominent early-stage AD fields such as MRI and biomarker research. Accordingly, most 
ADNI studies often assess episodic memory as part of a mixed predictive model with other 
AD markers (e.g., episodic memory and hippocampal atrophy model). Although the mixed-
predictive-model approach makes sense methodologically, in practice, most studies address 
episodic memory with little focus. Moreover, it is typical for studies that seek to predict 
early-stage AD to include episodic memory as a variable in a long list of many predictors; 
they thus do not study it comprehensively. The remaining few studies that do focus 
specifically on episodic memory often study only the correlational or predictive ability of one 
episodic-memory measure with one other disease marker, thereby limiting the ability of 
researchers to understand episodic memory in AD. While it is essential to study the 
interaction of episodic memory with other disease markers (e.g., Aβ), the mixed model 
approach has the result that episodic memory lacks specific and focused research. However, 
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mixed predictor model research still provides helpful information regarding the potential of 
episodic-memory measures as predictors of MCI to AD conversion. 
Mixed Neuroimaging and Episodic-Memory Models 
Accordingly, most if not all ADNI episodic memory studies combine episodic-
memory scores with neuroimaging measures or biomarkers. Specifically, MRI brain-atrophy-
and-volume measures are the most prominent markers assessed in conjunction with episodic-
memory tests. Specifically, researchers have found strong relationships between MTL 
atrophy (hippocampal and entorhinal volume/atrophy) and episodic-memory decline, as 
theorised in the component process model. For example, one study investigating an array of 
predictors discovered that neuroimaging measures of cortical thickness and episodic-memory 
scores best predicted the conversion from MCI to AD; however, the study concluded that 
neurobiological measures were overall worse than episodic-memory tests in predicting MCI 
to AD conversion (Gomar et al., 2011). In a follow-up study three years later, the same 
researchers assessed more predictors of conversion across the whole of the ADNI database 
and concluded that episodic-memory measures were the best predictors of MCI to AD 
conversion (Gomar, Conejero-Goldberg, Davies, Goldberg, & Alzheimer’s Disease 
Neuroimaging Initiative, 2014). Accordingly, there is contention concerning which 
neuroimaging and episodic-memory measure should be used to accurately predict early-stage 
AD.  
Ihara et al. (2018) have investigated episodic memory, hippocampal atrophy and Aβ 
aggregation in ADNI to understand the relationship and predictive ability of each measure. 
Ihara et al. (2018) reasoned that episodic-memory decline, hippocampal atrophy and Aβ 
accumulation are all linked, as theorised in the amyloid cascade hypothesis (see Section 1.2, 
p.3). However, the study also found that, while Aβ and hippocampal atrophy were related, 
episodic memory and Aβ were not (Ihara et al., 2018). The researchers reasoned that 
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episodic-memory decline in AD derives from hippocampal atrophy that is mediated by Aβ 
concentration. Moreover, Ihara et al. (2018) have further suggested that there is no direct 
relationship between Aβ concentration and episodic-memory decline. The relationship 
between MTL atrophy and episodic memory ability was further reinforced by a study which 
showed that MRI measures of atrophy could predict episodic memory performance in ADNI 
(Moradi, Hallikainen, Hänninen, Tohka, & Alzheimer’s Disease Neuroimaging Initiative, 
2017). However, there is a need for more research, as it is clear that no decisive episodic 
memory and neuroimaging model consistently predicts MCI to AD conversion. Thus, this 
project builds on past research by examining multiple neuroimaging and episodic-memory 
measures together to assess the predictive accuracy of a mixed model. 
Beyond atrophy, other neuroimaging studies have sought to determine how 
neurological connectivity affects episodic memory in ADNI by using functional MRI. 
Breakdowns in the communicative ability of the frontal temporal and thalamic regions in 
amnestic MCI participants are indicative of cognitive decline (Cai et al., 2015). However, 
little literature investigates neural connectivity in ADNI even though it is a fundamental 
aspect of the component process model of episodic memory. We theorise that the lack of 
clarity and consensus concerning neural connectivity (neural oscillations) occurs due to the 
lack of measures in the ADNI database. Specifically, ADNI only uses fMRI data to assess 
neuronal connectivity and not electroencephalographic measures which are preferred in the 
wider literature. Accordingly, this topic is beyond the scope of this research project and our 
acquired ADNI dataset. 
Mixed Biomarker and Episodic-Memory Models 
Traditional biomarkers, such as cerebrospinal fluid (CSF) and genes, are the other 
prominent AD markers which are studied alongside episodic memory in the ADNI database. 
The most prominent biomarkers studied in the ADNI database are the Aβ and tau CSF 
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markers. There are varying opinions regarding the viability of biomarkers in predicting AD 
and correlating with episodic memory. Some ADNI studies have found no relationship 
between Aβ and episodic memory (Gomar et al., 2011, 2014; Mormino et al., 2009); 
conversely, other studies have found evidence that Aβ and episodic memory correlate and can 
accurately predict MCI to AD conversion (Lin et al., 2017; Nathan et al., 2016; María J. 
Russo, Campos, Vázquez, Sevlever, & Allegri, 2017; María Julieta Russo et al., 2016; Seo et 
al., 2016). Thus, further research is required to determine the relationship between Aβ and 
episodic memory in AD. 
As with CSF biomarkers, genetic risk factors are also often assessed with episodic-
memory decline to predict early-stage AD. A small number of studies show positive results in 
predicting MCI to AD conversion and episodic-memory decline (Nathan et al., 2016; 
Ramanan et al., 2012); however, the literature is too small to conclude that genes can predict 
early-stage AD in the ADNI cohort. Furthermore, in the broader AD literature, genetic 
markers such as APOE4 have been rigorously investigated and shown to be mere risk factors 
of disease development (Povova et al., 2012). More research is required to understand the 
interaction of genes and CSF biomarkers in AD pathogenesis and their role in AD derived 
episodic-memory decline. Accordingly, current research would suggest that episodic memory 
best predicts MCI to AD conversion as a single measure or when combined with 
neuroimaging biomarkers. Consequently, this project focuses on predicting MCI to AD 
conversion using neuroimaging and episodic-memory measures. 
Individual Episodic-memory Predictors 
Outside of ADNI, a small number of studies have examined the ability of episodic-
memory measures to predict MCI to AD conversion and, thus, early-stage AD. A study by 
Chapman et al. (2011) investigated the ability of neuropsychological tests to predict AD and 
found that episodic memory could predict MCI to AD conversion. Specifically, they found 
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that episodic memory, when combined with recognition, visuospatial memory, and executive 
functioning measures, could predict disease conversion with an accuracy of 84%. Chapman et 
al. (2011) primarily used the LMT, RAVLT, MMSE, brief visuospatial memory test revised, 
and Hopkins verbal learning test to study episodic memory. The statistical analysis 
incorporated neuropsychological test scores into total scores (e.g., episodic-memory scores) 
using a principal component analysis. However, the individual predictive accuracy of each 
episodic-memory test was not thoroughly discussed or compared. Moreover, Chapman et al. 
(2011) concluded that a single episodic-memory measure could not predict MCI to AD 
conversion and so recommended using a mixed model containing various neuropsychological 
tests (e.g., visuospatial memory, executive functioning and episodic-memory measures). 
A more recent study by De Simone et al. (2019) examined the accuracy of specific 
episodic-memory tests when predicting MCI to AD conversion. De Simone et al. (2019), 
unlike prior researchers, analysed multiple episodic-memory measures; however, De Simone 
et al. (2019) combined them into total scores and did not report the accuracy of specific tests 
and measures. Nonetheless, De Simone et al. (2019) highlighted the potential of specific 
episodic-memory tests to predict MCI to AD conversion with a high accuracy. Accordingly, 
preliminary research has suggested that episodic-memory measures can predict MCI to AD 
conversion both individually and in a mixed model (Chapman et al., 2011; De Simone et al., 
2019; Gomar et al., 2011). However, in the literature, there are discrepancies in research 
results, as some studies do not evaluate each contained episodic-memory test or report 
accuracy measures. There is also contention concerning the relationship between episodic 
memory and neuroimaging measures in mixed predictive models. Moreover, some key areas 




Thus, building on the above research, this project seeks to assess ADNI participants 
across four years by using multiple general and specific episodic-memory measures (i.e., the 
ADAS-cog, MMSE, ADNIMEM, RAVLT, and LMT). Moreover, through ADNI, this project 
has access to more participants and variables (neuroimaging and biomarker) than prior 
studies such as Chapman et al. (2011). Furthermore, this project can also use a more 
sophisticated analysis to rigorously and longitudinally compare episodic-memory predictors 
of MCI to AD conversion. Like the study of De Simone et al. (2019), this study 
longitudinally and comprehensively examines the predictive accuracy of various episodic-
memory tests when predicting MCI to AD conversion. However, unlike De Simone et al. 
(2019), this project also does the following: A) tests the episodic-memory measures 
contained in the ADNI database (which to our knowledge has not been done before), B) uses 
a more complex logistic regression based predictive analysis, C) assesses neuroimaging 
predictors of conversion and mixed episodic-memory models, D) examines the predictive 
ability of general and specific episodic-memory measures, and, most importantly E) reports 





1.5 The Present Study 
Past studies have examined the ability of various cognitive measures and biomarkers 
to predict MCI to AD conversion and, subsequently, early-stage AD. However, there is 
disagreement amongst researchers regarding the reliability, validity, and accuracy of the 
varying individual measures of early-stage AD. For example, traditional biomarkers have a 
poor predictive accuracy which impedes early-stage AD diagnosis. Cognitive measures (e.g., 
standard tests) are often regarded as ineffective measures of early-stage AD, as they mostly 
assess the later symptoms of the disease; however, little research has been conducted on 
specific tests that target the initial cognitive symptoms of early-stage AD, such as episodic 
memory loss. Across the AD literature, episodic memory is consistently regarded as a strong 
predictor of AD development; yet episodic memory loss is not widely understood in early-
stage AD. 
Accordingly, this study seeks to investigate the predictive ability of episodic-memory 
measures in the ADNI database to inform current early-stage AD theory and diagnostic 
methods. Most ADNI studies rely heavily on the RAVLT as a single measure of episodic 
memory and do not comprehensively assess episodic memory. Moreover, to our knowledge, 
no study has sought to test and evaluate all the episodic-memory measures in the ADNI 
database for their predictive ability. Thus, this study tests and evaluates all measures of 
episodic memory in the ADNI database for their accuracy in predicting MCI to AD 
conversion. The evaluation of episodic-memory tests involved studying each measure both 
individually and in mixed cognitive and neuroimaging marker models. Specifically, this 
study seeks to create the best episodic-memory predictor model and compare it to 
neuroimaging predictor models, which are the preferred measures in the literature. Moreover, 
by comparing the accuracy of episodic memory and neuroimaging models, we can theorise 
how these measures interact and determine whether significant memory decline occurs before 
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or after neurodegeneration. Thereby, informing theories of episodic-memory decline and 
early-stage AD progression, such as the amyloid cascade hypothesis and component 
processing model. 
Importantly, this study assesses each episodic-memory measure across each year of 
ADNI’s second cohort. It was essential to study each year separately, as theory states that 
different episodic-memory tests optimally predict AD at different points in time during 
conversion; however, episodic-memory tests were also evaluated for their overall predictive 
accuracy across the whole cohort. It was also important that general episodic-memory 
measures (e.g., standard tests that can measure episodic memory such as the MMSE) be 
compared to specific episodic-memory measures, thus determining the ability of specific tests 
compared to standard tests in the ADNI database and early-stage AD research. 
 
Accordingly, this project aims to do the following: 
• Assess whether general cognitive assessment tests such as the MMSE and ADAS-
Cog can measure episodic memory. 
• Determine which episodic-memory tests can best predict MCI to AD conversion 
individually and in a mixed model. 
• Investigate whether neuroimaging predictors can outperform or improve episodic-
memory predictive models. 
We hypothesise that hippocampal atrophy and specific episodic-memory scores (e.g., 
LMT) are the best predictors of MCI to AD conversion. We further hypothesise that an 
aggregate score of all episodic-memory tests performs better than each memory test 
individually. Moreover, we predict that a mixed episodic-memory and neuroimaging model 
will best predict MCI to AD conversion in the ADNI cohort. 
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It is important to note that this study does not seek to understand every facet of 
episodic-memory decline in early-stage AD. This study only seeks to understand early-stage 
AD using episodic-memory measures in the confines of the ADNI cohort. Moreover, this 
study is not a dictionary for episodic-memory measures but rather an evaluation of the 
potential of episodic-memory measures in early AD research. This report comprises an 
original contribution to the discussion and investigation of pathological markers in AD and a 
much needed discussion on the state of cognitive research in neuroscience. We expect that 
this project will result in a deeper understanding of episodic-memory decline in early-stage 
AD and the theoretical processes of episodic memory. Furthermore, we expect that the 
information gathered from this study will contribute to the pool of knowledge that will, in the 
future, improve cognitive tests and their ability to detect early-stage AD. This study seeks to 
provide an original contribution to the understanding of episodic memory and AD detection 
and prediction strategies. Consequently, our long-term goal is to contribute to the 
improvement of early-stage AD detection and, subsequently, to improve the quality of life of 
those with AD. 
With the above background, aims, and literature review in mind, the following 
chapters explore the associated methodology, analysis, and discussion. Specifically, Chapter 
2 outlines the methods and measures that are used to address the above aims and hypotheses. 
Next, Chapter 3 details the statistical analysis and answers our research questions. Finally, 
Chapter 4 discusses the outcomes of this study as well as detailing future directions for early-




Chapter Two: Methods 
 
2.1 Design and Methodology 
As discussed in the introduction (p. 22), this study seeks to predict MCI to AD 
conversion using measures of episodic memory. Furthermore, this study aims to evaluate 
current episodic-memory tests and determine which memory measures best predict early-
stage AD. This study also seeks to investigate episodic-memory measures in comparison to 
neuroimaging measures and discusses the subsequent theoretical implications of our results. 
This chapter details the sample population, dataset, variables, methodology and statistical 
analysis used in this study. Particularly, this chapter seeks to outline the reasoning, tools, and 
methods that were used to transform the aims from Chapter 1 into the statistical analysis and 
results detailed in Chapters 3 and 4.   
Accordingly, a quantitative design is used to compare control (MCI stable) and 
experimental groups (MCI to AD converters) as well as evaluate the predictive nature of 
episodic-memory and neuroimaging measures. Moreover, a predictive analysis is used to 
detect AD conversion over the four years of the ADNI2 cohort. This study assessed 
participants at yearly intervals, as most, if not all, of the measures contained were recorded 
annually. Participants came from a volunteer sample population and were initially sorted into 
control, MCI and AD diagnosis groups by ADNI. For this project, participants were further 
classified into MCI stable and MCI (to AD) converting groups. All data in this project was 
received from ADNI. The quality and complexity of the information received from the ADNI 
database surpass that of any information that can be collected during a one-year project and is 





For the statistical analysis, a principal component factor analysis was used to assess 
the construct validity of episodic-memory tests. Moreover, the factor analysis also 
determined whether the MMSE and ADAS-cog could measure episodic memory. For the 
main analysis, a binary logistic regression was used to predict MCI to AD conversion in MCI 
participants. The logistic regression tests the predictive accuracy of conversion of individual 
and mixed models against the observed conversion accuracy in the ADNI database. Binary 
logistic regressions were also used to determine the accuracy and predictive odds of 
neuroimaging measures and mixed models. All assumptions of a binary logistic regression 





2.2 Data Source and Acquisition 
The Alzheimer’s Disease Neuroimaging Initiative was formed in 2004 as a publicly 
and privately funded entity that explores AD biomarkers and disease prediction strategies. 
Most importantly, ADNI provides all of its data to researchers for free, as discussed in 
Section 1.3.2 above (p. 7). The initiative has studied four cohorts over its history, with 
participants both carrying over from prior research and new participants being added at the 
beginning of each new initiative. ADNI studies typically last five years to allow sufficient 
time for longitudinal participant assessment. Upon the initiation of a new ADNI cohort, new 
biomarkers and research methodologies are added to keep the initiative up to date with the 
current AD literature. However, because of the gradual iteration of the ADNI cohorts, it is 
sometimes hard to examine measures across the cohorts. In order, the ADNI cohorts thus far 
have been the following: the ADNI1, the ADNIGO, the ADNI2 and the ADNI3 cohort. 
The ADNI2 cohort is the chosen sample for this study because, out of all four ADNI 
cohorts, the ADNI2 study is the one most recently finished. The current ADNI3 cohort is still 
in process, thus limiting sample numbers and the availability of longitudinal participant 
results. The ADNI2 cohort went for five years from 2011 to 2016 with participants’ data 
recorded at annual or biannual intervals depending on the measures in question. The ADNI2 
cohort consists of 700 participants from previous initiatives and 150 cognitively healthy 
controls, 100 early MCI (EMCI), 150 late MCI (LMCI), 150 AD participants, and a new 
criterion of 107 participants with a significant memory concern (SMC). The SMC 
participants are, categorically, control subjects at a higher risk of disease conversion 
appearing on the AD spectrum between healthy ageing and MCI individuals. 
The specific dataset we used was the ADNIMERGE.csv file, which incorporates the 
most common AD measures in all participants from all initiatives. The measures contained in 
the dataset include the most commonly used demographic, neuroimaging, biomarkers, and 
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neuropsychological measures, according to the literature. In the ADNIMERGE datafile 
participants data is recorded annually; however, if a participant misses a study interval, his or 
her data is omitted. The only prerequisite for obtaining ADNI data was institutional ethics 
approval. Accordingly, this study gained ethics approval from Western Sydney Universities 
Human Research Ethics Committee in March of 2019. All statistical analysis was performed 





2.3 Participants and Groups 
ADNI2 consists of two main streams of participants: those overlapping from prior 
ADNI cohorts and newly recruited participants. The prior ADNI1 and ADNIGO cohorts 
carried over approximately 700 participants to ADNI2 out of their original 1000 recruits. As 
previously noted, the new ADNI2 recruits consist of approximately 150 CN, 100 SMC, 100 
EMCI, 150 LMCI and 150 AD participants. ADNI recruited all participants for ADNI2 via 
print and new media advertising, third-party healthcare providers or previous initiatives. 
Since the ADNI data is open to the general science community, all participant data is de-
identified for ethical reasons. Our participants formed two groups dictated by their diagnosis 
over the whole of ADNI2. Participants were sorted into a conversion group if they converted 
from MCI to AD over the five years and into a non-converter group if they remained stable 
over the five years. Subsequently, CN and SMC participants were not studied, as this study is 
only interested in MCI to AD conversion. Moreover, it was important to maintain only two 
groups throughout the study so that binary logistic regressions could be used for the analysis. 
The resulting population contained 95 converters and 212 non-converters overall with a total 
population of N = 307 participants. These groups were made to accurately address whether 
disease markers could predict MCI to AD conversion. When working with atypical 
neurological populations and the elderly, it is natural to experience mortality and participant 
drop out, due to the vulnerability of the population. Because of the nature of our population, 
corrections needed to be made in the form of multiple imputations to reduce the bias created 
by the exponential and longitudinal increase in missing data. Missing data and multiple 




2.4 Variables and Measures 
All available episodic memory and neuroimaging variables for ADNI2 were extracted 
from the ADNIMERGE dataset. The ADNIMEM composite memory score was also included 
from an auxiliary dataset, as this score can measure episodic memory (it contains items from 
the RAVLT and LMT) and is computed from data contained in the ADNIMERGE dataset. 
Although our research questions do not concern demographical measures such as age or 
education, these measures were kept as descriptive statistics to enable us to better understand 
our population. The specific measures contained in this study are detailed in what follows. 
2.4.1 Episodic-Memory Measures 
The RAVLT is a specific episodic-memory tests and is the most commonly used test 
for assessing episodic memory in the ADNI literature. The RAVLT is a list learning task that 
tests word recall using multiple trials after as time delay. Specifically, participants are given a 
list of words and then, after a break, they are asked to identify those words in a larger word 
list. Most of the episodic-memory tests used by ADNI contain multiple measures that 
examine different facets of episodic memory (e.g., ADAS-cog and RAVLT). The ADNI and 
ADNIMERGE data sets contain four measures of episodic memory which use the RAVLT. 
First, the RAVLT immediate score measures participant word recall after the first list 
learning trial. Second, the RAVLT learning score measures the number of words remembered 
across all trials. Next, the RAVLT forgetting score measures the number of words from the 
original word list missed over all trials. Finally, the RAVLT percent forgetting score is a 
different quantification of the prior RAVLT forgetting score. In the literature, RAVLT 
immediate and forgetting variables are the most common measures of episodic memory used 
and tend to have the best accuracy when predicting MCI to AD conversion. 
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The LMT is the second specific episodic-memory tests used by ADNI and is based on 
the Weschler Memory Scale. As discussed in Section 1.4.2 above (see p.14), the test uses a 
recall task centred around a short story to test episodic memory. The LMT is often used in 
clinical practice to provide evidence for an AD diagnosis or to monitor at-risk patients such 
as individuals with MCI. The ADNI database records the LMT as a single score of delayed 
recall; however, few of the papers which assess episodic memory in the ADNI database have 
used the LMT and have instead relied too much on the RAVLT. Outside of the ADNI 
database and early-stage AD research, the LMT commonly has a high accuracy when 
detecting AD. 
The ADAS-cog is a general multi-domain test or standard test that is widely used in 
AD diagnosis. The ADAS-cog involves various tasks in areas such as language, delayed 
word recall, comprehension and word recognition. The specific tasks vary depending on the 
version of the ADAS-cog. Accordingly, the ADNI2 cohort and the ADNIMERGE datasets 
contain the 11(ADAS 11) and 13 (ADAS 13) task versions of the ADAS-cog. The ADNI 
database also contains the ADASQ4 measure, which is the fourth section of the ADAS-cog, 
which measures delayed recall. The ADASQ4 is included in the ADNIMERGE dataset, as it 
is a specific measure of delayed recall and thus of episodic memory. 
The MMSE is also a general multi-domain test (standard test) that is widely used in 
dementia research and clinical diagnosis. Moreover, the MMSE is often used outside of 
dementia research to assess cognitive ability. The MMSE is a 30-item questionnaire that 
assesses multiple cognitive domains and tests abilities such as recall, naming and orientation. 
The ADNI database records MMSE scores as a total score.  
The final episodic-memory measure is the ADNI composite memory score 
(ADNIMEM). ADNI calculates ANIMEM by using specific items from the RAVLT, ADAS-
cog, LMT and MMSE scores. The ADNIMEM scores are calculated using item response 
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theory methods across all four of the tests (see Crane et al., 2012, for more information). The 
ADNIMEM score is available to all researchers with access to the ADNI database and is 
theorised to be better than individual measures of episodic memory (Crane et al., 2012). The 
ADNIMEM score is not contained in the ADNIMERGE dataset; however, the data used to 
calculate it is contained therein. It is unknown why ADNIMEM is not initially contained in 
the ADNIMERGE dataset, as that is the file its data originates from. Thus, we treated it as an 
ADNIMERGE measure and included it in our dataset. 
2.4.2 Alzheimer’s Disease Neuroimaging Markers 
The ADNIMERGE dataset contains volumetric neuroimaging measures for the 
majority of participants throughout all cohorts. Participant data was initially collected by 
ADNI on site or through certified partner organisations such as universities or the Mayo 
Clinic. ADNI often outsources the collection and management of its neuroimaging data to 
partner companies and institutions, and the Mayo Clinic handles most of the neuroimaging 
data. The University of California San Francisco (UCSF) processes and analyses all of the 
neuroimaging data used in this study as part of a partnership with ADNI. ADNI2 and UCSF 
use FreeSurfer software to clean and analyse raw MRI data. In this case, FreeSurfer was 
explicitly used to visually reconstruct the cortex and segment brain regions into volumes for 
analysis. For more information about FreeSurfer, see the Athinoula A. Martinos Center for 
Biomedical Imaging (2019), and for more information about UCSF methods, see the 
Alzheimer’s Disease Neuroimaging Initiative (2017). The volumetric neuroimaging variables 
contained in the analysis were determined via ADNI according to the literature. The specific 




Initially, our analysis sought to contain more neuroimaging variables; however, much 
of the wider ADNI neuroimaging data available is either not for ADNI2, did not contain 
enough participants or did not contain the measures we needed to address our hypothesis. 
Furthermore, when trying to assimilate new neuroimaging data into our file, there was too 
much missing data to warrant adding new neuroimaging variables. The problems with 




2.5 Data Pre-processing and Population 
The ADNI data is broad. It contains approximately 100 different variables across all 
participants at every temporal stage of all ADNI cohorts. Due to the broad and general nature 
of the dataset, the data needed to be cleaned to fit our research project. We first removed all 
participants from all cohorts outside of the ADNI2 population. ADNI2 was the best 
population available, as it contains the most recent measures of the completed ADNI studies. 
Next, we removed all participants who originated from initiatives outside of the ADNI2 
cohort. The varying ADNI initiatives used different measures and variables that are not 
interchangeable across cohorts, thereby limiting comparisons. Subsequently, this study 
removed participants who had baseline measures before the initiation of ADNI2, as their 
measures differed from those of new subjects. Other studies have attempted to compare 
variations in ADNI measures across initiatives and have found inconsistency. Consequently, 
we thought it best to control for ADNI cohort variations by only using participants 
originating in ADNI2. 
After we had defined our population, the two conversion groups were created using a 
filter command in SPSS. Participants were extracted into the conversion group if they were 
diagnosed with MCI at baseline and developed AD at any yearly reporting session after 
(Select participant if [Base Line Diagnosis ~= AD & Diagnosis = AD]). Participants who 
remained stable were selected if they were diagnosed with MCI at baseline and remained 
with MCI throughout the study (Select participant if [Base Line Diagnosis = EMCI | Base 
Line Diagnosis = LMCI] & [Diagnosis = MCI]). For some unknown reason, the 
ADNIMERGE dataset reports MCI participants as EMCI or LMCI at baseline; during all 
follow up sessions, however, it only reports these participants as having MCI. Thus, in the 
analysis, we had to treat all EMCI and LMCI participants as MCI due to measurement 
changes made by ADNI. Next, because this filter only pulled out participants’ data in the year 
35 
 
they converted or were stable, we extracted participants’ data in each group using their ID 
number and cross-referenced the lists to make sure there was no participant overlap in our 
groups. Finally, the data was filtered by year because of participant mortality and for the 
analysis. As the study progressed, participants increasingly missed annual recordings, so the 
data was moderated by yearly intervals so that participant mortality would not confound 
conversion statistics over time. For a more detailed example of our data pre-processing 
procedure, see Gomar et al. (2011 & 2014). 
Upon completion of the data cleaning, we merged the ADNI composite memory score 
from another file. The merge data sets command in SPSS was used to include the composite 
memory variable and match it to our participant rosters at the appropriate annual recording 
intervals. It was essential to include ADNIMEM to test whether a combined episodic-
memory score could better predict AD than individual cognitive tests, as seen in (Crane et al., 
2012). Thus, inclusion of the composite memory score was necessary for completing our 
research goal, which was to assess the viability and predictive ability of all ADNI episodic-
memory measures. Other potential biomarker and neuroimaging measures in the ADNI 
database were cross-referenced with our sample to see if we could include more variables; 
however, none both, applied to the ADNI2 dataset and did not have severe levels of missing 
data. Once our population was defined and our dataset was sufficiently cleaned, we started 




2.6 Preliminary Analyses 
2.6.1 Sample Size and Descriptive Statistics 
Before conducting the initial analysis, descriptive statistics and a G*Power analysis 
were run so we could better understand our population and required sample size. Specifically, 
we used measures of diagnosis, participant counts, and group sizes to better understand our 
sample. Furthermore, descriptive statistics were run on participants’ age, sex and education to 
help us understand our participant sample compared to other studies. In total, our analysis 
contained five descriptive, ten episodic-memory, and six neuroimaging variables. A sample 
size analysis was run using the software, G*Power, developed by the University of 
Düsseldorf, Germany (Faul, Erdfelder, Buchner, & Lang, 2009; Faul, Erdfelder, Lang, & 
Buchner, 2007). Since we are using logistic regression, the z-test a priori settings were used 
to compute a recommended sample size from an alpha error probability of 0.05, a statistical 
power of 0.95, a conversion probability of 0.2 and a populations parameter of 0.45 in a 
binomial distribution. The recommended sample size was 37 participants, which we exceeded 
in all years of ADNI2 besides year five. The low sample size cut off occurred primarily 
because we were testing the dichotomous group fit, which is easy to compute due to the 
limited outcomes. It is important to report, for replication's sake, that our G*Power analysis 
resulted in a critical z of -1.96 and an actual power of 0.953. As previously mentioned, the 
final year of ADNI2 (year five) did not reach the recommended sample size and was 
therefore excluded from the analysis. Accordingly, in total, our analysis contained 307 





2.6.2 Missing Data   
Early on in the draft analysis, we discovered a significant portion of participants’ data 
had been omitted due to data missing across multiple variables. We ran a missing values 
pattern analysis to visualise the data and inform the best way to fix the problem of missing 
data. Usually, a study would omit missing values if under five per cent; however, this was not 
a comprehensive solution. All of the episodic-memory measures contain approximately 2% 
missing data, which means that we could omit the missing data. Figure 1 below shows the 
percentage of missing data relative to all participants and variables. While there was only a 
small number of missing values, the study kept filtering out participant data in a listwise 
fashion. Incorrectly, if a participant was missing a single entry for a variable, the analysis 
filtered him or her out of the study. 
Upon further investigation, we determined that there was a severe amount of missing 
neuroimaging data in years three and four of ADNI2. To be precise, an average of 85% of all 
neuroimaging data was missing from these two years. Comparatively, an average of 20% of 
participants’ neuroimaging data was missing in years one and two of the ADNI2 cohort. As 
Figure 1. Visual representation of missing values across ADNI2 where: Variable = number of missing variables, 





the missing data was so large for the latter two years of ADNI2, there was no option but to 
remove the neuroimaging data for those years and to study neuroimaging markers only in the 
first two years of the ADNI2 cohort. The 20% of missing data in the first years was fixed 





To remedy the missing values, we used multiple imputation corrections to infer new 
values from the existing data (Manly & Wells, 2015). Multiple imputations work by 
computing probable values for missing data based on the existing patterns of variables in the 
dataset and a random number generator. The imputations for each variable are calculated 
multiple times orthogonally from each other, then pooled together and averaged to get the 
final imputed statistic. Using SPSS, multiple imputations were formulated using the 
Mersenne Twister random number generator and the monotonic method set to six 
imputations. We followed the guidelines and methodology for running multiple imputations 
suggested by Manly and Wells (2015) and Sterne et al., (2009). All variables were used to 
Variables 
Missing 
Valid N Mean SD 
N Per cent 
UCSF Med Temp 150 26.7% 412 19476.70 3193.474 
UCSF Fusiform 150 26.7% 412 17669.77 3287.481 
UCSF Entorhinal 150 26.7% 412 3397.98 888.682 
UCSF Ventricles 114 20.3% 448 40511.12 25597.710 
UCSF Whole Brain  79 14.1% 483 1031415.44 114270.456 
UCSF Hippocampus  74 13.2% 488 6575.64 1412.750 
Variables 
Missing Valid N Mean SD 
N Per cent 
UCSF Med Temp 322 88.2% 43 19632.00 3792.481 
UCSF Fusiform 322 88.2% 43 17541.09 3637.192 
UCSF Entorhinal 322 88.2% 43 3328.56 868.462 
UCSF Ventricles 320 87.7% 45 42865.89 24493.282 
UCSF Whole Brain  315 86.3% 50 1018675.72 126639.129 
UCSF Hippocampus  308 84.4% 57 6474.85 1409.024 
Table 2  
Missing Data in Years Three and Four of ADNI2 
 
Note. SD = Standard deviation, N = Participant cases 
 
Note. SD = Standard deviation, N = Participant cases 
 
Table 1 





calculate multiple imputations; however, in the analysis, imputations were used only for 
neuroimaging variables, as episodic-memory variables were missing only 2% of data. As a 
general rule, multiple imputations work best for variables which are missing less than 50% of 
their data. As the two years of neuroimaging data was missing only approximately 20%, this 
rule of thumb was met. Originally, we wanted to use CSF biomarkers (Aβ and Tau) in this 
analysis; however, too much data was missing (approximately 90%) to run multiple 
imputations and use the variables.  
We hypothesize that missing data has resulted from problems with participant 
dropout, participant comfort and the flexibility of our data file. First, with a neurologically 
vulnerable population, it is understandable to have a gradual drop off of missing data as 
observed across the years of our ADNI sample. Second, uncomfortable and invasive 
procedures such as MRI or the lumbar punctures used to obtain participant information work 
on an opt-in/opt-out approach. Participants can choose when they want to partake in research 
and the attached medical procedures due to the ethical rules put in place to protect participant 
consent and wellbeing. Subsequently, when participants can choose which medical 
procedures to undertake, there is a chance to obtain less data. For example, it is not surprising 
to see that CSF data has the most missing values, as it is the most invasive of the procedures 
and would deter the most participants. Lastly, we hypothesize that a large section of the 
missing data comes from our manipulation of the original data file. It is apparent that the 
ADNI data was not collected explicitly for our study and accordingly does not fit perfectly; 
however, there is still ample data available with which to address our research questions, and 




2.7 Analysis Outline 
The analysis contained four parts, one for each year of ADNI2 studied. Each year 
individually assessed all three research questions derived from the aims specified in Section 
1.5 (p.23). Initially, we wanted to include all five years of ADNI2; however, the last year did 
not have enough participants to warrant analysis when accounting for participant drop-out 
and missing data. For the first research question, we sought to evaluate the construct validity 
of general AD diagnostic tests to see if they could measure episodic memory. For the second 
research question, we wanted to test which episodic-memory measure best predicted MCI to 
AD conversion and to determine whether a mixed episodic-memory model could predict 
conversion better than individual tests. Finally, we sought to create a mixed predictor model 
of MCI to AD conversion using both episodic memory and neuroimaging variables. 
Specifically, we sought to test if a mixed predictor model could predict MCI to AD 
conversion better than prior episodic-memory models and compare the predictive ability of 
neuroimaging measures to episodic-memory tests. 
2.7.1 Research Question One Outline 
Research Question One: Can general cognitive assessment tests for AD, such as the MMSE 
and ADAS-Cog, measure episodic memory?  
Before conducting the majority of the analyses and evaluating the tests, we wanted to 
double check the construct validity of our episodic-memory measures. Specifically, in the 
literature, it is theorised that the standard dementia diagnostic tests such as the ADAS-cog 
and MMSE can be used to assess episodic memory (Crane et al., 2012; Gomar et al., 2011); 
however, we wanted to test the construct validity of these tests before assuming that they are 
episodic-memory tests. To test the construct validity of these AD tests, we ran a factor 
analysis to see if the general AD assessment tests function using the same underlying factors 
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as the specialised episodic-memory tests. We specifically used a principal component 
analysis with a varimax rotation to easily separate variables into potential factors. The results 
of the factor analysis and subsequent construct validity of the ADAS-cog and MMSE were 
taken into account when we performed the primary analysis. 
2.7.2 Research Question Two Outline 
Research Question Two: Which episodic-memory test best predicts MCI to AD conversion, 
and can a mixed episodic-memory model predict conversion better in each year of the ADNI2 
cohort? 
A binary logistic regression was used to formulate a model that could predict MCI to 
AD conversion in converter and non-converter groups. Usually, a linear regression would be 
favoured for predictive analyses; however, because this is secondary (previously collected) 
and longitudinal data, a logistic regression fit best due to its retrospective nature. Moreover, a 
logistic regression also fit our analysis best, as our dependant variable was a dichotomous 
categorical variable (disease conversion). Due to the secondary nature of our data, 
participants could be categorised into conversion groups based on their diagnosis history in 
the cohort, which means that we could test the accuracy of our predictive models against the 
reality of participant conversion in the cohort. Accordingly, we inferred the conversion 
variable from ADNI’s measure of participant diagnosis across the four years of the initiative. 
The first series of logistic regressions was used to determine the predictive ability of 
each episodic-memory test. Accordingly, we performed a logistic regression on each 
episodic-memory variable and tabulated the results. Each episodic-memory variable was 
ranked in order of predictive ability according to measures of accuracy, odds ratio, accounted 
variance and significance, which were determined by chi-squared, r-squared and Pearson’s p-
values. Accuracy was tested for by cross-referencing our model’s classification of conversion 
in participants with their actual conversion in the initiative, as recorded by ADNI. This 
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analysis ran automatically as part of a logistic regression in IBM SPSS 26. We also used the 
Hosmer-Lemeshow test of sphericity as an indicator of model fit. While researchers debate 
the usefulness of the Hosmer-Lemeshow test in logistic regressions, we included the test as 
an indicator of model fit and did not use it as a statistical cut off for our analysis. We 
evaluated all individual episodic-memory predictors for predictive ability by using binary 
logistic regressions in all four years of ADNI2. Once the individual episodic-memory 
variables had their predictive ability determined, we put them together to formulate a mixed 
episodic-memory predictive model of MCI to AD conversion.  
To create the best mixed model, we expanded upon the binary logistic regression 
design used for the individual predictors above. A block-wise hierarchical binary logistic 
regression was used to find the best predictive model. In the literature, multiple studies use 
stepwise regression methods to construct mixed predictive episodic-memory models, but 
these methods are often open to suppression effects that create preference biases for 
variables. To avoid suppression effects, we used a forced entry hierarchical method that 
enters variables individually in blocks and in order of importance, which is determined by the 
researcher. The block hierarchical method allows predictors that have historically performed 
best to go first while also lessening the suppression effects of latter variables by adding them 
in individually and in accord with their importance. We entered the ADNIMEM score first, as 
composite memory scores are theorised to be better than individual episodic-memory scores 
in AD research. Next, we gradually entered the RAVLT and LMT episodic-memory tests due 
to their reputation and prominence in the literature. Finally, we added in the ADAS-cog and 
MMSE tests, as they are general assessment tests that do not explicitly test episodic memory 
but are theorised to do so. Variables in the mixed model were removed or kept depending on 
significance, chi-squared, accuracy and R-squared statistics, as was done previously. To be 
counted the best predictive model, the model must have had the best balance of accounted 
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variance and accuracy while containing only significant predictors. It is important to note that 
these episodic-memory mixed models were run without imputations, as they can lead to high 
correlations between variables and effect multicollinearity. 
It was imperative to check the assumptions of a binary logistic regression before 
interpreting our results. All of the assumptions—dichotomous dependent variable, multiple 
continuous or categorical independent variables and independence of observations—were 
passed by our basic research design and methodology. The assumption of the linearity of the 
logit was tested by creating log versions of our variables and testing the interaction between 
the original variables and its log form in logistic regression. If the results of the interaction 
were nonsignificant in the regression, then the assumption was met. We did not assess the 
assumption of multicollinearity during the individual predictor's stage, as only one variable 
was studied at a time; however, we assessed the assumption of multicollinearity during the 
mixed model analysis by running collinearity tests contained in linear regression analysis in 
SPSS. Multicollinearity was assessed using tests of tolerance and variance inflation factor 
(VIF). When assessing multicollinearity, to meet the assumption of multicollinearity, the 
general rule is that tolerance should be above 0.1 and VIF less than 10. The results of the 
assumption checks dictated the analysis and interpretation of our results. 
2.7.3 Research Question Three Outline 
Research Question Three: Which neuroimaging markers best predict MCI to AD conversion, 
and can a mixed model predict conversion better than prior models in each year of the 
ADNI2 cohort? 
For the third research question, we ran an analysis similar to the one we ran for 
Research Question 2; however, this time, the binary logistics regression contained the 
neuroimaging variables. We first analysed each predictor individually for predictive ability 
by using a binary logistic regression. We then checked the assumption of the logit with log 
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forms of each variable, as in Research Question 2. Next, we created a mixed model using a 
hierarchical binary logistic regression. This time variables were entered in blocks of two, 
organised by the type of variable and its importance to the literature. It was not possible to 
enter variables individually as done in the mixed episodic-memory analysis, as there were too 
many variables that would have made the analysis cumbersome and unwieldy. The software 
IBM SPSS statistics also does not allow for the individual addition of so many variables 
during a logistic regression; thus, we were forced to use a multiple variable block-wise 
method. We used the individual predictive ability of each variable to dictate the order within 
blocks and variables history in the literature. Accordingly, episodic-memory variables were 
entered in first followed by neuroimaging measures. Variables were once again removed or 
kept in the model depending on their R-squared measure, significance and accuracy in 
predicting disease conversion. We then checked the assumptions of multicollinearity and 
linearity of the logit on the best predictive model. 
Following the completion of the assumption checks, the best mixed predictor model 
was compared with the best individual and mixed episodic-memory models in the appropriate 
year to determine which measure best predicted MCI to AD conversion overall. It is 
important to note that all of the variables in the mixed model analysis, except for the 
episodic-memory variables, contained multiple imputations. Though the use of multiple 
imputation corrections for data is permissible and widely accepted in the literature, we were 
careful in interpreting the results; however, not using any statistical corrections would have 
resulted a worse circumstance with mostly biased results. The interpretation of multiple 
imputations is discussed further in Chapter 4 (p.72). 
In conclusion, this chapter detailed the sample population, variables, data, and 
statistical methods used in this study. Firstly, the ADNI2 sample and MCI-converter and MCI 
non-converter groups were discussed. Next, we discussed the ADNI database and 
45 
 
ADNIMERGE dataset, including a list of episodic memory and neuroimaging variables. 
Subsequently, the G*Power analysis, pattern analysis, multiple imputation corrections, and 
problems with missing data were also detailed. Lastly, the statistical analysis and 






Chapter Three: Results 
 
3.1 Descriptive Statistics 
This study investigates the predictive ability of episodic-memory measures in the 
ADNI database to inform current early-stage AD theory and detection methods. Specifically, 
this study compares general-multidomain tests and specific episodic-memory tests. 
Moreover, this study also predicts MCI to AD conversion using various episodic-memory 
and neuroimaging markers.  
ADNI2 
Year 
Variable N Minimum Maximum Mean SD 
1 Age 301 55.0 91.4 71.693 7.3329 
Education 301 9 20 16.32 2.654 
2 Age 261 55.0 91.4 71.372 7.4096 
Education 261 9 20 16.28 2.648 
3 Age 214 55.0 88.6 71.217 7.1362 
Education 214 9 20 16.28 2.653 
4 Age 151 55.0 88.4 70.621 6.7987 
Education 151 12 20 16.11 2.551 
5 Age 27 55.0 82.2 68.878 7.4641 
Education 27 12 20 16.26 2.566 
Before the primary analysis, descriptive statistics and frequency analyses were run to 
understand our ADNI2 sample population. Table 3 above summarises the age and 
educational statistics of all participants organised by each year of ADNI2. Each year of 
ADNI2 in the analysis contained participants with similar age distributions and educational 
values. Specifically, in the five years of the ADNI2 cohort, participants had an approximate 
mean age of 70, an age range of 55-91 and a standard deviation of seven years. Participants’ 
educational levels remained constant with a mean of 16, a range of 9-20 and a standard 
Note. SD = Standard deviation, N = Participant count 
 
Table 3 
Participant Count, Age, and Education Descriptive Statistics 
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deviation of 2.6 across all four years of ADNI2. This meant that, although the ADNI2 cohort 
had gradual participant drop out, our sample stayed relatively consistent. 
Our study contained 307 participants (N = 307) across the first four years of ADNI2. 
However, there was a gradual drop off of participants in our sample, with year one containing 
301 participants, year two containing 261 participants, year three containing 214 participants, 
year four containing 151 participants, and year five containing 27 participants. Accordingly, 
year five was the only sample that we could not study, as the subject count did not reach the 
37 participants recommended by the G*Power analysis (see Section 2.6.1 p.36). In our 
sample, MCI participants remained the largest group throughout, consisting of approximately 
74% of all participants. Accordingly, AD participants made up approximately 26% of our 
sample (see Table 4 below).  
Year  Diagnosis Frequency Percent 
1 AD 36 12.0 
MCI 265 88.0 
Total 301 100.0 
2 AD 59 22.6 
MCI 199 76.2 
Total 261 100.0 
3 AD 56 26.2 
MCI 153 71.5 
Total 214 100.0 
4 AD 41 39.4 
MCI 104 60.6 
Total 145 100.0 
From the diagnosis statistics observed across ADNI2, we were able to determine participant 
conversion and group participants. The AD conversion and non-conversion groups were 
pivotal in testing our model’s accuracy in comparison to the observed conversion in ADNI2. 
Because our sample consisted of only MCI participants at baseline, the conversion statistics 
were the same as the percentage of AD participants. Thus, approximately 20-25% of our 
Table 4 
Participant Diagnosis Across ADNI2 




participants converted from MCI to AD, which is in agreement with the MCI to AD 
conversion rate observed across the literature (Mitchell & Shiri-Feshki, 2009). Fewer 
participants converted to AD in the first year of ADNI2 (12%), which is to be expected, as 
AD progression is exponentially related to age. On average, 48 participants converted to AD 
from MCI in each year of ADNI2, and 180 remained stable with MCI. 
It is also important to note that, in the ADNIMERGE datafile, all MCI participants 
were split into EMCI and LMCI groups at baseline but only categorised as MCI participants 
in follow-up sessions. It was therefore impossible to analyse the different forms of MCI, as 
EMCI and LMCI were not distinguished in the dataset. Consequentially all instances of 
LMCI and EMCI were treated as purely MCI. The same scenario occurred for SMC 
participants who became normal controls. The operationalisation of MCI participants is 
further discussed in Section 2.5 above (p. 34).  
Lastly, before progressing to the main analysis, it is important to explore the 
assumption that episodic-memory declines over time in AD participants. If episodic memory 
does not decline over time in our population, we cannot use episodic-memory measures to 
predict the disease. Accordingly, we ran descriptive statistics for each cognitive test and 
tabulated the means across the four years of ADNI2 in MCI converters and non-converters. 
Specifically, standardised averages (Z-scores) were used to compare the episodic-memory 
tests, as various tests had different base scales that initially hindered comparison. 
Furthermore, note that higher scores on the ADAS 11, 13, Q4, and RAVLT percent forgetting 
tests indicate poor memory performance while lower scores on the MMSE, LMT, 
ADNIMEM and all other RAVLT measures indicate poor memory performance. 
Accordingly, cognitive ability worsened across all episodic-memory measures across the four 




Comparatively, stable MCI participants remained relatively the same, which is to be 
expected (see Figure 3, p.50). There was little variation is scores over time, with most 
standardised averages varying only within a hundredth of their initial score in the first year 
of ADNI2. Therefore, it is safe to assume that episodic memory worsens over time in AD 
participants (MCI converters) and remains comparatively stable in MCI non-converters. 
Furthermore, the observed patterns in episodic-memory decline in this study align with those 
observed in the literature. 
Figure 2. Standardised averages of episodic-memory scores in MCI converting participants across the first four 







Figure 3. Standardised averages of episodic-memory scores in MCI stable participants across the first four years 




Note. Only MCI converter cases were used in the principal component 
analysis 
 
3.2 Research Question One 
A principal component factor analysis was used to test the assumption that general 
AD diagnostic tests can measure episodic memory. Specifically, the factor analysis assessed 
construct validity between episodic-memory tests and general AD tests in hope that they 
would all measure episodic memory in AD. Ten episodic-memory measures were assessed 
originating from four main groups of tests: the RAVLT, MMSE, LMT and ADAS-cog (see 
Section 2.2 for more information). Before running the full analysis, the Kaiser-Myer-Olkin 
(KMO) Measure of Sampling Adequacy and Bartlett's Test of Sphericity were used to check 
the viability of running a factor analysis on these variables. 
 Loadings  
EM Measures Factor One: Factor Two: Communality 
ADAS13 -.904 .147 .838 
ADNI_MEM .928 -.225 .912 
ADAS11 -.843 .048 .712 
RAVLT Immediate .802 -.019 .643 
ADASQ4 -.718 .415 .689 
MMSE .665 .062 .446 
LMT .549 -.486 .538 
RAVLT Learning .606 -.133 .385 
RAVLT Forgetting .286 .900 .892 
RAVLT % Forgetting -.438 .840 .898 
    
 Eigenvalue 4.932 2.022  
 % of Total variance 49.316 20.219  
 Total Variance  69.534%  
 
In year one of ADNI2, we were cleared to run our analysis because Bartlett’s test was 
significant [p= <.001] and because KMO = .672, which is above the required minimum of 
0.6. A varimax rotation was used to clarify factor loadings, as there was some overlap in 
factors. Our principal component analysis resulted in two factors being extracted according to 
an eigenvalue of one, which resulted in an explained total variance of 70% amongst all 
variables (see Table 5 above). Factor 1 confirmed our assumption that the general AD tests 
Table 5 
Principal Component Analysis ADNI2 Year One 
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were highly related to the episodic-memory tests and could independently measure episodic 
memory. Factor 2 appeared only to contain the RAVLT forgetting measures, which is 
understandable, as they are both variants of the same measure. Accordingly, in the first year 
of ADNI2, all cognitive measures, including standard tests, could measure episodic memory.  
 Loadings  
EM Measures Factor One: Factor Two: Communality 
ADAS13 -.895 .244 .861 
ADNI_MEM .904 -.300 .908 
ADAS11 -.864 .139 .766 
RAVLT Immediate .902 -.020 .813 
ADASQ4 -.613 .601 .737 
MMSE .717 -.126 .530 
LMT .496 -.630 .643 
RAVLT Learning .663 -.137 .459 
RAVLT Forgetting .657 .682 .896 
RAVLT % Forgetting -.141 .909 .846 
    
 Eigenvalue 5.205 2.253  
 % of Total variance 52.054 22.534  
 Total Variance  74.588%  
The second year of ADNI yielded results similar to those obtained the first year. We 
were cleared to run our analysis, as the KMO test was above the 0.6 threshold [KMO = .740] 
and because Bartlett’s test was significant [p= <.001]. Once again, a varimax rotation was 
used to separate factors into more distinct groups, and an eigenvalue of one was used to 
define the number of factors. The principal component analysis resulted in an explained total 
variance of 75% (see Table 6 above). As in the first year, Factor 1 confirmed our assumption 
that the general AD tests were highly related to the episodic-memory tests and could 
independently measure episodic memory. Again as in the first year, Factor 2 appeared to 
contain the RAVLT forgetting measures due to their similarity but also contained the LMT; 




Principal Component Analysis ADNI2 Year Two 
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however, the LMT and RAVLT forgetting measures were still highly prominent in the first 
factor. Accordingly, the analysis once again suggested that all tests were related enough to 
measure episodic memory due to sharing the same primary factor.  
 Loadings  
EM Measures Factor One: Factor Two: Communality 
ADAS13 -.849 .394 .877 
ADNI_MEM .770 -.596 .947 
ADAS11 -.863 .293 .831 
RAVLT Immediate .857 -.311 .831 
ADASQ4 -.280 .840 .785 
MMSE .819 -.235 .726 
LMT .171 -.903 .845 
RAVLT Learning .235 -.508 .313 
RAVLT Forgetting .783 .317 .714 
RAVLT % Forgetting -.023 .925 .857 
    
 Eigenvalue 4.241 3.485  
 % of Total variance 42.409 34.852  
 Total Variance  77.261%  
In the third year of ADNI2, the principle components analysis contained two factors 
similar to those observed in prior years; however, in the third year, the factors had larger 
differences in values. The third-year analysis used the same rotation and eigenvalue for the 
extraction, but we had to limit the analysis to two factors. The factors were limited to two, as 
the analysis was extracting a third factor that was relatively useless and only just over the 
eigenvalue cut-off. As in prior years, the KMO [KMO = .711] and Bartlett's Test of 
Sphericity [p= <.001] indicated that the data met the assumptions of a principal component 
analysis. The two factors explained a total variance of 77% but were more evenly distributed 
compared to prior years (see Table 7 above). Factor 1 contained the general tests and the 
RAVLT Immediate and forgetting. Factor 2 was comprised of all the delayed recall measures 
and contained the ADASQ4, LMT, RAVLT Learning and RAVLT percent forgetting. While 
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there was still an overlap between specific episodic-memory tests and general standard tests, 
it was strange to see a greater divide later on in ADNI2. Accordingly, the divide between 
tests may provide evidence for the theory that different tests optimally measure episodic 
memory during different stages of AD progression.  
 Loadings  
EM Measures Factor One: Factor Two: Communality 
ADAS13 -.892 .381 .941 
ADNI_MEM .877 -.407 .935 
ADAS11 -.882 .299 .867 
RAVLT Immediate .921 -.149 .869 
ADASQ4 -.660 .622 .822 
MMSE .859 -.134 .756 
LMT .384 -.759 .723 
RAVLT Learning .448 -.227 .252 
RAVLT Forgetting .726 .602 .890 
RAVLT % Forgetting -.183 .916 .872 
    
 Eigenvalue 5.273 2.655  
 % of Total variance 52.727 26.550  
 Total Variance  79.277%  
In the final year of ADNI2, our analysis returned to the two factor loadings observed 
in the first two years. A KMO of .790 and a significant Bartlett’s test [p= <.001] indicated 
that we were clear to run our analysis. In the fourth year, the analysis found two factors, 
which means that there was no need to restrict the factor loadings as in the previous year. The 
two factors explained a total variance of 79%, with factor one accounting for the most 
variance (52%) (see Table 8 above). All measures were related in Factor 1 with the exception 
of the RAVLT percentage forgetting score. Factor 2 contained the delayed recall tests like the 
third year, yet in year four, the factor only had a small contribution. Thus, all tests appear to 
measure the same episodic memory construct. 
In conclusion, across all four years studied in ADNI2, general memory tests and 
specific episodic-memory tests were related enough to assume that general memory tests can 
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assess episodic memory. This means that the rest of the analysis can investigate how well all 
these tests can measure episodic memory in MCI and AD. Accordingly, general and specific 





3.3 Research Question Two 
A binary logistic regression was run on each episodic-memory predictor in each year 
of ADNI2 to determine their sole predictive abilities. Following the analysis of individual 
predictors, all episodic-memory measures were combined by using a hierarchical binary 
logistic model to form a mixed predictive model of MCI to AD conversion.  
      95% C.I. for Exp(B) 
EM Measures B S.E. Wald Sig. Exp(B) Lower Upper 
ADNI_Mem -1.950 .096 412.857 .000 .142 .118 .172 
RAVLT Forgetting .058 .019 9.308 .002 1.059 1.021 1.099 
RAVLT Immediate -.122 .007 331.591 .000 .885 .873 .897 
Logical Memory Test -.310 .015 433.988 .000 .733 .712 .755 
RAVLT Percent Forgetting .030 .002 267.456 .000 1.031 1.027 1.034 
RAVLT Learning -.371 .023 256.490 .000 .690 .660 .722 
ADAS 13 .177 .009 423.350 .000 1.193 1.173 1.213 
MMSE -.381 .023 271.007 .000 .683 .653 .715 
ADAS Q4 .450 .023 386.623 .000 1.569 1.500 1.641 
ADAS 11 .237 .012 382.434 .000 1.267 1.238 1.298 
3.3.1 ADNI2 Year One 
In the first year of ADNI2, all of the episodic-memory variables could significantly 
predict MCI to AD conversion except for the RAVLT Forgetting. The predictive odds, 
significance and confidence intervals of each individual episodic-memory measure is detailed 
in Table 9 above. Initially, the ADASQ4 had an odds ratio of Exp(β) = 1.569 and was 
positively predicting conversion with better odds than any other variable [β = 0.450, z = 
386.623, p < .001]; however, the LMT, ADASQ4, RAVLT Forgetting and RAVLT Percent 
Forgetting all violated the assumptions of a binary logistic regression. Therefore, out of the 
interpretable results, the ADAS11 had the best predictive odds [Exp(β) = 1.267]. The odds of 
Table 9 
Individual Episodic Memory Predictors of MCI to AD Conversion in Year One of ADNI2 
Note. Highlighted variables violated assumption checks and could not be interpreted           
B = Regression coefficient used to calculate Exp(B) 




the ADAS11 were followed by the ADAS13 [Exp(β) = 1.193], RAVLT Immediate [Exp(β) = 













ADNI_Mem .286 .402 709.297 .000 56.4 78.1 
RAVLT Forgetting .004 .006 9.372 .002 0.0 68.8 
RAVLT Immediate .227 .319 541.876 .000 41.4 72.4 
Logical Memory Test  .269 .378 658.881 .000 60.6 77.7 
RAVLT Percent 
Forgetting 
.154 .217 352.418 .000 63.8 71.7 
RAVLT Learning .142 .200 322.400 .000 38.1 75.0 
ADAS 13 .274 .385 672.581 .000 50.2 77.5 
MMSE .149 .210 340.442 .000 23.4 71.4 
ADAS Q4 .226 .318 540.637 .000 53.2 75.7 
ADAS 11 .247 .348 598.100 .000 42.6 77.4 
After taking the odds ratios into account, the best individual predictive episodic-
memory measure was determined according to accuracy, chi-squared, accounted variance and 
significance, as seen in Table 10 above. The accounted variance was reported using Cox and 
Snell’s R-squared (C&S R2) and Nagelkerke’s R-squared (N-R2) measures. Initially, the 
specific episodic-memory measures (ADASQ4, LMT etc.) had the best predictive accuracy, 
yet they had to be omitted because they violated the assumptions of linearity of the logit. Of 
the remaining measures, the ADNIMEM composite memory score had the best accuracy and 
accounted variance when predicting MCI to AD conversion [C&S R2 = .286, Nagelkerke R2 
= .402, Conv-Acc. = 56.4%, p < .001]. The next best individual episodic-memory predictors 
of MCI to AD conversion were the ADAS13 [Conv-Acc. = 50.2%], ADAS11 [Conv-Acc. = 
42.6%], RAVLT Immediate [Conv-Acc. = 41.4%]. Interestingly, the RAVLT Forgetting, 
which is the most common episodic-memory measure in the literature, could not predict MCI 
to AD conversion. Accordingly, ADNIMEM was the best individual episodic-memory 
predictor of MCI to AD conversion in the first year of ADNI2. It should also be noted that 
Table 10 
Accuracy and Accounted Variance of Individual Episodic Memory Predictors in Year One of ADNI2 
 
Note. Highlighted variables violated assumption checks and could not be interpreted           
C&S R2 = Cox & Snell R-squared  




some researchers may opt to use the ADAS13 over the ANIMEM because it has a better odds 
ratio with a similar accuracy. 
Mixed Episodic-Memory Predictor Model 
Whilst multiple predictors of MCI conversion were found, a true accuracy as fair as 
56% and 50% is not good enough for clinical or academic use. We therefore investigated 
whether a mixed episodic-memory model could predict MCI to AD conversion better than 
our individual episodic-memory models. We used a hierarchical binary logistic regression to 
create a mixed episodic-memory predictor model for the first year of ADNI2. The best model 
consisted of the ADASQ4 and RAVLT Immediate, as seen in Table 11 below. The odds 
ratios of the mixed model were better than those of the ADNIMEM and the other 
interpretable individual predictors. The model odds when predicting conversion for the 
ADASQ4 and RAVLT Immediate were Exp(β) = 0.925 and Exp(β) = 1.324, respectively. It 
is important to note that, when part of a mixed model, the ADASQ4 did not violate any 
assumptions of a logistic regression and thus could be used in this stage of the analysis.  
      95% C.I. for Exp(B) 
EM Measures B S.E. Wald Sig. Exp(B) Lower Upper 
RAVLT Immediate -.078 .008 98.489 .000 .925 .911 .939 
ADAS Q4 .281 .028 101.285 .000 1.324 1.254 1.399 
Constant .011 .363 .001 .976 1.011   
For the predictive accuracy and accounted variance of the mixed episodic-memory 
predictor model, see Table 12 below. The mixed episodic-memory model [C&S R2 = .266, N-
R2 = .310, Conv. Accuracy = 53.1%, p < .001] accurately predicted MCI to AD conversion 
worse than the ADANIMEM individual model (but only marginally worse). On all counts 
besides conversion accuracy, the mixed model was better than ADNIMEM; however, the 
Table 11 
The Best Mixed Episodic-Memory Model Predicting MCI to AD Conversion in ADNI2 Year One 
B = Regression coefficient used to calculate Exp(B) 
Exp(B) = predictive odds ratio 




differences between each model was so marginal that the models could be considered equal. 
Once again, the accuracy of the mixed model was not close to research or clinical standards 
for diagnostic and predictive tests. 










.266 .374 650.207 .000 53.1 77.1 
3.3.2 ADNI2 Year Two 
      95% C.I. for Exp(B) 
EM Measures B S.E. Wald Sig. Exp(B) Lower Upper 
ADNI_Mem -2.240 .112 402.790 .000 .106 .086 .132 
RAVLT Forgetting .100 .019 27.591 .000 1.105 1.065 1.148 
RAVLT Immediate -.124 .007 313.531 .000 .883 .871 .896 
Logical Memory Test -.396 .018 460.720 .000 .673 .649 .698 
RAVLT Percent Forgetting .039 .002 277.774 .000 1.039 1.035 1.044 
RAVLT Learning -.362 .025 208.274 .000 .696 .663 .731 
ADAS 13 .207 .010 436.523 .000 1.230 1.206 1.254 
MMSE -.427 .024 325.185 .000 .652 .623 .683 
ADAS Q4 .564 .027 431.223 .000 1.758 1.667 1.854 
ADAS 11 .290 .014 404.279 .000 1.337 1.299 1.375 
In the second year of ADNI2, all individual episodic-memory measures could predict 
MCI to AD conversion besides RAVLT Forgetting, just as in the first year. However, overall, 
episodic-memory measures performed better in the second year than they did in the first year. 
Both the LMT and MMSE violated the assumption of linearity of the logit and could, 
consequentially, not be interpreted. The ADASQ4 [Exp(β) = 1.758, β = .564, z = 431.223, p < 
.001] had the best odds ratio when predicting MCI to AD conversion out of all individual 
Table 12 
Accuracy and Accounted Variance of the Mixed Episodic Memory Model in Year One of ADNI2 
C&S R2 = Cox & Snell R-squared  
N-R2 = Nagelkerke R-squared 
 
Table 13 
Individual Episodic Memory Predictors of MCI to AD Conversion in Year Two of ADNI2 
 
Note. Highlighted variables violated assumption checks and could not be interpreted           
B = Regression coefficient used to calculate Exp(B) 
Exp(B) = predictive odds ratio 




episodic-memory measures, as seen in Table 13 above. The ADAS 11 [Exp(β) = 1.337], 
ADAS13 [Exp(β) = 1.230], and RAVLT Forgetting [Exp(β) = 1.105] followed, with similar 
increases in disease conversion odds. 
When assessing accounted variance and predictive accuracy with the above odds, the 
best individual predictor was the RAVLT Percent Forgetting [C&S R2 = .213, N- R2 = .297, 
Conv-Acc. = 71.7%, p < .001]. The RAVLT Percent Forgetting was followed in predictive 
accuracy by the ADAS 13 [Conv-Acc. = 69.8%], ADASQ4 [Conv-Acc. = 66.3%] and the 
ADNIMEM [Conv-Acc. = 63.9%] in predictive accuracy. Although the RAVLT Percent 
Forgetting did have a lover accounted variance compared to most predictors, the ADAS13 
had the best balance of odds, accounted variance and accuracy; however, with cognitive tests, 
a higher predictive accuracy is often preferred; thus, the RAVLT Percent Forgetting would 













ADNI_Mem .358 .501 797.755 .000 63.9 81.6 
RAVLT Forgetting .016 .022 28.184 .000 0.0 66.9 
RAVLT Immediate .255 .356 527.911 .000 51.8 76.4 
Logical Memory Test  .382 .533 862.725 .000 70.7 81.1 
RAVLT Percent 
Forgetting 
.213 .297 429.404 .000 71.7 75.6 
RAVLT Learning .139 .194 268.613 .000 34.9 71.1 
ADAS 13 .386 .539 875.889 .000 69.8 84.3 
MMSE .233 .326 477.476 .000 44.6 76.3 
ADAS Q4 .324 .452 699.946 .000 66.3 82.0 
ADAS 11 .366 .511 817.625 .000 60.2 82.4 
To determine whether we could improve upon our individual predictor models, we 
used a hierarchical binary logistic regression to discover the best mixed episodic-memory 
model in the second year of ADNI2; however, no significant mixed episodic-memory model 
could be found that matched or outperformed our individual RAVLT Percent Forgetting or 
Table 14 
Accuracy and Accounted Variance of Individual Episodic Memory Predictors in Year Two of ADNI2 
 
Note. Highlighted variables violated assumption checks and could not be interpreted           
C&S R2 = Cox & Snell R-squared  




ADAS13 models. This was, in part, due to high amounts of multicollinearity between 
variables. It is unclear why multicollinearity was such a large issue in the second year and not 
in the first year of ADNI2. Consequently, the RAVLT Percent Forgetting remained the best 
episodic-memory predictor of MCI to AD conversion in the second year of ADNI2. 
3.3.3 ADNI2 Year Three 
In the third year of ADNI2, individual episodic-memory predictors generally 
improved in predictive accuracy. Unlike prior years, all measures met the assumptions of the 
linearity of the logit and could therefore be interpreted. All individual episodic-memory 
measures were significant with the exception of the RAVLT forgetting variable. Accordingly, 
the best odds ratio of all individual episodic-memory predictors in the third year of ADNI2 
was once again the ADASQ4 (see Table 15 below). Specifically, the ADASQ4 [β = 0.608, z 
= 383.384, p < .001] had a positive odds increase of Exp(β) = 1.837 when predicting 
conversion. TheADASQ4 was followed by the ADAS11 [Exp(β) = 1.365], ADAS13 [Exp(β) 
= 1.262] and the RAVLT Percent Forgetting [Exp(β) = 1.045] in predictive odds.  
      95% C.I. for Exp(B) 
EM Measures B S.E. Wald Sig. Exp(B) Lower Upper 
ADNI_Mem -2.445 .134 333.229 .000 .087 .067 .113 
RAVLT Forgetting .025 .023 1.248 .264 1.026 .981 1.072 
RAVLT Immediate -.151 .009 283.746 .000 .860 .845 .875 
Logical Memory Test -.367 .019 358.583 .000 .693 .667 .720 
RAVLT Percent Forgetting .044 .003 262.105 .000 1.045 1.039 1.050 
RAVLT Learning -.405 .027 228.073 .000 .667 .633 .703 
ADAS 13 .233 .012 351.517 .000 1.262 1.232 1.293 
MMSE -.597 .032 338.741 .000 .551 .517 .587 
ADAS Q4 .608 .031 383.384 .000 1.837 1.728 1.952 
ADAS 11 .311 .017 340.292 .000 1.365 1.320 1.410 
 
Table 15 
Individual Episodic Memory Predictors of MCI to AD Conversion in Year Three of ADNI2 
B = Regression coefficient used to calculate Exp(B) 
Exp(B) = predictive odds ratio 




The predictive accuracy and accounted variance of each individual episodic-memory 
predictor can be found in Table 16 below. Overall, episodic-memory predictors exhibited a 
better accuracy predicting conversion in the third year of ADNI2 than in prior years. The 
LMT [C&S R2 = .374, N-R2 = .521, Conv-Acc. = 76.9%, p < .001] was the single best 
predictor followed by the ADASQ4 [Conv-Acc. = 71.6%], the ADNIMEM [Conv-Acc. = 
67.6%], and the ADAS13 [Conv-Acc. = 67.3%]. The RAVLT Forgetting was the only 
episodic-memory measure that could not predict MCI to AD conversion, as in prior years. 
The LMT did not contain the best accounted variance or odds ratio; however, when its strong 













ADNI_Mem .409 .571 766.886 .000 67.6 83.2 
RAVLT Forgetting .001 .001 1.247 .264 0.0 67.4 
RAVLT Immediate .321 .447 561.585 .000 55.6 76.9 
Logical Memory Test  .374 .521 679.139 .000 76.9 82.9 
RAVLT Percent 
Forgetting 
.248 .346 413.650 .000 67.1 75.3 
RAVLT Learning .200 .279 324.256 .000 51.2 74.0 
ADAS 13 .453 .631 876.677 .000 67.3 85.5 
MMSE .389 .543 716.585 .000 59.1 83.3 
ADAS Q4 .364 .508 655.406 .000 71.6 82.1 
ADAS 11 .425 .593 805.531 .000 65.8 84.5 
Mixed Episodic-Memory Predictor Model   
In the third year of ADNI2, the best mixed episodic-memory predictive model of MCI to AD 
conversion contained the LMT, the ADNIMEM, and the ADASQ4 measures. The LMT 
[Exp(β) = 0.855], the ADNIMEM [Exp(β) = 0.287], and the ADASQ4 [Exp(β) = 1.145] all 
predicted an increase in conversion odds (see Table 17 below). These predictive odds were 
worse than most of the individual predictors in the third year. 
 
Table 16 
Accuracy and Accounted Variance of Individual Episodic Memory Predictors in Year Three of ADNI2 
 
C&S R2 = Cox & Snell R-squared  




      95% C.I. for Exp(B) 
EM Measures B S.E. Wald Sig. Exp(B) Lower Upper 
ADNI_MEM  -1.250 .219 32.535 .000 .287 .186 .440 
Logical Memory  -.157 .024 41.174 .000 .855 .815 .897 
ADAS Q4  .136 .053 6.644 .010 1.145 1.033 1.269 
Constant -1.007 .364 7.652 .006 .365   
 
Overall, the mixed episodic-memory model [Conv-Acc. = 77.7%, p < .001] 
performed like the LMT [Conv-Acc. = 76.9%, p < .001], which was the best individual 
episodic-memory predictor in terms of conversion predictive accuracy. However, the mixed 
model accounted for more variance [C&S R2 = .428, N-R2 = .598] when predicting MCI to 
AD conversion compared to the LMT [C&S R2 = .374, N-R2 = .521] (see Table 18 below). 
Moreover, the conversion predictive accuracy [Conv-Acc. = 77.7%] and total predictive 
accuracy [Total Acc. = 85.3%] of the third-year mixed models are more in line with research 
and clinical standards. The mixed model as a whole is only just better than individual 
episodic-memory predictors of conversion; however, the disparity between models is 
arguably not large enough to justify using three measures (including the LMT) compared to 
just using the LMT.  
EM Measures C&S R2 N-R2 Chi-squared Sig. Conv Acc. Total Model Acc. 
Mixed EM Model Y3 .428 .598 808.244 .000 77.7 85.1 
 
Table 17 
The Best Mixed Episodic Memory Predictor Model in Year Three of ADNI2 
B = Regression coefficient used to calculate Exp(B) 
Exp(B) = predictive odds ratio 
S.E. = Standard Error 
 
Table 18 
The Accounted Variance and Accuracy of the Best Mixed episodic Memory Model in Year Three of ADNI2 
C&S R2 = Cox & Snell R-squared  




3.3.4 ADNI2 Year Four 
In the final year of ADNI2, our analysis confirmed the trend that episodic-memory 
measure accuracy improves over time. The odds ratios were almost identical to those of the 
third year with the multiple ADAS-cog measures and RAVLT Percent Forgetting having the 
best predictive odds (see Table 19 below). Specifically, the ADASQ4 [Exp(β) = 1.891] had 
the best predictive odds followed by the ADAS11 [Exp(β) = 1.299], ASAD13 [Exp(β) = 
1.219] and the RAVLT Percentage Forgetting [Exp(β) = 1.037].  
      95% C.I. for Exp(B) 
EM Measures B S.E. Wald Sig. Exp(B) Lower Upper 
ADNI_Mem -2.284 .149 233.721 .000 .102 .076 .136 
RAVLT Forgetting .018 .029 .372 .542 1.018 .962 1.077 
RAVLT Immediate -.142 .010 199.219 .000 .868 .851 .885 
Logical Memory Test -.311 .021 220.538 .000 .733 .703 .763 
RAVLT Percent Forgetting .037 .003 148.148 .000 1.037 1.031 1.043 
RAVLT Learning -.402 .037 121.157 .000 .669 .623 .719 
ADAS 13 .198 .012 252.225 .000 1.219 1.189 1.249 
MMSE -.547 .035 248.935 .000 .579 .541 .619 
ADAS Q4 .637 .039 266.060 .000 1.891 1.751 2.041 
ADAS 11 .262 .017 238.778 .000 1.299 1.257 1.343 
As observed in prior years, RAVLT Forgetting could not predict MCI to AD 
conversion and was not significant. In the fourth year, the best individual episodic-memory 
predictor was the LMT. It predicted MCI to AD conversion with an accuracy of 77.2% (see 
Table 20 below). The LMT was followed by the ADAS13 [Conv-Acc. = 75.5%] and the 
ADASQ4 [Conv-Acc. = 75.0%] in predictive ability. The LMT did not have the best 
accounted variance [C&S R2 = .327, N-R2 = .461] and was greatly surpassed by the ADAS13 
[C&S R2 = .431, N-R2 = .608] and the ADASQ4 [C&S R2 = .363, N-R2 = .513]. Accordingly, 
the ADASQ4 is equally viable, as it has the best balance of high accounted variance, 
predictive ability and odds ratio. Either the LMT, the ADASQ4 or the ADAS13 could be 
Table 19 
Individual Episodic Memory Predictors of MCI to AD Conversion in Year Four of ADNI2 
B = Regression coefficient used to calculate Exp(B) 
Exp(B) = predictive odds ratio 




considered the best predictive measures of MCI to AD conversion depending on research 
preferences. We consider the ADASQ4 to be the best predictor of MCI to AD conversion due 













ADNI_Mem .400 .563 521.400 .000 71.1 85.6 
RAVLT Forgetting .000 .001 .372 .542 0.0 69.4 
RAVLT Immediate .301 .425 364.931 .000 57.1 78.6 
Logical Memory Test  .327 .461 403.133 .000 77.2 84.1 
RAVLT Percent 
Forgetting 
.191 .270 216.294 .000 65.3 72.2 
RAVLT Learning .144 .204 158.846 .000 40.1 74.1 
ADAS 13 .431 .608 574.623 .000 75.5 88.3 
MMSE .415 .586 548.715 .000 73.3 87.7 
ADAS Q4 .363 .513 457.133 .000 75.0 85.5 
ADAS 11 .406 .573 531.548 .000 73.2 87.6 
Note that we attempted to formulate a mixed episodic-memory predictor model in the 
fourth year of ADNI2; however, as with the second year, no model was found that could 




Accuracy and Accounted Variance of Individual Episodic Memory Predictors in Year Four of ADNI2 
 
C&S R2 = Cox & Snell R-squared  




3.4 Research Question Three 
After we had formulated our episodic-memory prediction models, we sought to assess 
the predictive ability of the neuroimaging predictors of MCI to AD conversion in the first two 
years of ADNI2. We sought to assess the individual predictive ability of each neuroimaging 
variable by using a binary logistic regression. Following the individual analysis, we used a 
hierarchical binary logistic regression to determine whether neuroimaging measures could 
improve prior episode memory predictive models. The third and fourth years of ADNI2 could 
not be assessed due to problems with missing data that are discussed in Section 2.6.2 (p. 37). 
ADNI2 Year One 
In the first year of ADNI2, the individual neuroimaging markers were tested for their 
predictive odds and accuracy. All variables were statistically significant yet had problematic 
odds ratios [approximately Exp(β) = 1.00] (see Table 21 below). This meant that we could 
not interpret the odds ratios; however, we could infer from the Wald statistics that the 
entorhinal [z = 32.048] and hippocampal [z = 30.879] variables were the best models.  
      95% C.I. for Exp(B) 
AD Markers B S.E. Wald Sig. Exp(B) Lower Upper 
UCSF Ventricles .000 .000 5.736 .038 1.000 1.000 1.000 
UCSF Hippocampus -.001 .000 30.879 .000 .999 .999 1.000 
UCSF Whole Brain .000 .000 6.733 .025 1.000 1.000 1.000 
UCSF Entorhinal -.001 .000 32.048 .000 .999 .998 .999 
UCSF Fusiform .000 .000 15.833 .001 1.000 1.000 1.000 
UCSF Med Temp .000 .000 19.031 .001 1.000 1.000 1.000 
All of the variables performed very poorly when predicting MCI to AD conversion, as 
can be seen in Table 22 below. The best individual predictor of conversion was the entorhinal 
variable [Conv-Acc. = 27.85%], followed by hippocampal volume [Conv-Acc. = 27.32%]. 
Table 21 
Individual Neuroimaging Predictor Odds of MCI to AD Conversion in Year One of ADNI2 
B = Regression coefficient used to calculate Exp(B) 
Exp(B) = predictive odds ratio 




All models performed worse than chance when predicting MCI to AD conversion. Moreover, 
individual neuroimaging variables also performed worse than episodic-memory measures in 
the first year of ADNI2. The accounted variance of entorhinal volume [C&S R2 = .120, N-R2 
= .169], the best neuroimaging predictor, was also far worse than the ANIMEM [C&S R2 = 














UCSF Ventricles .020 .027 5.79 .030 1.95 68.15 
UCSF Hippocampus .115 .161 36.601 .000 27.32 71.58 
UCSF Whole Brain .023 .032 7.005 .017 1.07 68.85 
UCSF Entorhinal .120 .169 38.455 .000 27.85 71.26 
UCSF Fusiform .057 .081 17.783 .000 8.17 69.17 
UCSF Med Temp .067 .095 21.133 .000 14.17 69.55 
Mixed predictor Model 
In the first year of ADNI2, the best mixed neuroimaging and episodic-memory model 
contained the ADAS11, the LMT and the entorhinal variables (see Table 23). The odds ratio 
positively predicted disease conversion similarly to each variable in their individual models.  
     95% C.I. for Exp(B) 
Mixed Measures B S.E. Sig. Exp(B) Lower Upper 
ADAS 11  .130 .037 .000 1.139 1.060 1.225 
Logical Memory  -.190 .046 .000 .827 .756 .905 
UCSF Entorhinal .000 .000 .044 1.000 .999 1.000 
Constant .528 .978 .590 1.695 .247 11.615 
 
Table 22 
Accuracy and Accounted Variance of Individual Neuroimaging Predictors in Year One of ADNI2 
B = Regression coefficient used to calculate Exp(B) 
Exp(B) = predictive odds ratio 
S.E. = Standard Error 
 
Table 23 
The Best Mixed Predictor Model of MCI to AD Conversion in Year One of ADNI2 
C&S R2 = Cox & Snell R-squared  




The mixed model predicted MCI to AD conversion with a higher accuracy than both 
the individual and composite episodic-memory models. Specifically, the mixed model 
predicted disease conversion with an accuracy of 59.8% compared to the 56.4% conversion 
accuracy of the ADNIMEM model (see Table 24 below). Accordingly, the mixed 
neuroimaging and episodic-memory predictive model was the best model in the first year of 
ADNI2. However, it could be argued that the individual episodic-memory models are more 
practical while containing similar accuracies.  
Mixed Measures C&S R2 N-R2 Chi-squared Sig. Conv Acc. Total Model Acc. 
Mixed Model Y1 .323 .454 117.315 .000 59.8 80.4 
ADNI2 Year Two 
      95% C.I. for Exp(B) 
AD Markers B S.E. Wald Sig. Exp(B) Lower Upper 
UCSF Ventricles .000 .000 6.912 .022 1.000 1.000 1.000 
UCSF Hippocampus -.001 .000 37.006 .000 .999 .999 .999 
UCSF Whole Brain .000 .000 7.680 .016 1.000 1.000 1.000 
UCSF Entorhinal -.001 .000 38.019 .000 .999 .998 .999 
UCSF Fusiform .000 .000 17.822 .002 1.000 1.000 1.000 
UCSF Med Temp .000 .000 22.626 .000 1.000 1.000 1.000 
When assessing the predictive ability of individual neuroimaging variables in the 
second year, an improvement in predictive ability was achieved compared to the first year; 
however, the odds ratios were still problematic. Specifically, almost all variables have a 
positive odds ratio of Exp(β) = 1.00 and could thus not be interpreted; however, the Wald 
Table 24 
The Accuracy and Accounted Variance of the Best Mixed Model in Year One of ADNI2 
Table 25 
The Best Mixed Predictor Model of MCI to AD Conversion in Year Two of ADNI2 
B = Regression coefficient used to calculate Exp(B) 
Exp(B) = predictive odds ratio 
S.E. = Standard Error 
 
C&S R2 = Cox & Snell R-squared  




statistic indicated that the entorhinal [z = 38.019], hippocampal [z = 37.006] and MTL [z = 
22.626] models outperform the others (see Table 25 above). 
The average accounted variance and predictive accuracy of the neuroimaging 
variables in the second year of ADNI2 was generally worse than the episodic-memory 
measures in the same year. The entorhinal [Conv-Acc. = 49.1%], hippocampal [Conv-Acc. = 
47.4%] and MTL [Conv-Acc. = 30.3%] models had the best accuracy when predicting MCI 
to AD conversion (See Table 26 below). All remaining variables performed poorly in 
comparison when predicting disease conversion. The entorhinal [C&S R2 = .174, N-R2 = 
.243], hippocampal [C&S R2 = .169, N-R2 = .235] and MTL [C&S R2 = .097, N-R2 = .135] 
models also had the best accounted variance.  
AD Markers C&S R2 N-R2 
Chi-
squared 
Sig. Conversion Acc. Total Accuracy 
UCSF 
Ventricles 
.027 .038 7.131 .017 4.4 67.97 
UCSF 
Hippocampus 
.169 .235 47.432 .000 42.4 75.08 
UCSF Whole 
Brain 
.031 .044 8.101 .009 4.2 68.17 
UCSF 
Entorhinal 
.174 .243 49.142 .000 43.4 75.17 
UCSF 
Fusiform 
.077 .107 20.539 .000 19.68 71.07 
UCSF Med 
Temp 
.097 .135 26.151 .000 30.3 73.27 
Mixed predictor Model 
A hierarchical binary logistic regression was run in year one of ADNI2 using both 
neuroimaging and episodic-memory variables. The aim was to see if a mixed predictor model 
could outperform our prior episodic-memory models. The best mixed model contained the 
ADAS13 and entorhinal variables (see Table 27 below). The odds ratios were similar to each 
Table 26 
The Accuracy and Accounted Variance of the Best Mixed Model in Year Two of ADNI2 
C&S R2 = Cox & Snell R-squared  




measure’s predictive odds in their individual models observed above. Moreover, the 
entorhinal variable still had problematic odds ratios. 
     95% C.I. for Exp(B) 
Mixed Measures B S.E. Sig. Exp(B) Lower Upper 
ADAS 13 .188 .027 .000 1.207 1.145 1.273 
UCSF Entorhinal -.001 .000 .018 .999 .999 1.000 
Constant -1.930 1.176 .103 .145 .014 1.483 
The accuracy and accounted variance of the mixed predictor model performed slightly 
worse than the episodic-memory models observed in the second year of ADNI2 (see Table 28 
below). However, the model performed worse by a negligible amount. Accordingly, the 
mixed neuroimaging model could be used to predict MCI to AD conversion, yet it would not 
realistically be used, as a single episodic-memory test can achieve the same results at a lower 
cost. Thus, the predictor of MCI to AD conversion in the second year of ADNI 2 was the 




N-R2 Chi-squared Sig. Conv Acc. Total Model Acc. 
Mixed 
Model Y2 
.408 .570 134.789 .000 70.5 83.9 
In conclusion, Chapter 3 investigated the ability of general-multidomain tests (i.e., 
MMSE and ADAS-cog) to measure episodic memory. Moreover, Chapter 3 investigated the 
ability of episodic-memory tests and neuroimaging measures to predict MCI to AD 
conversion. The results indicated that general-multidomain tests measured the same construct 
as specific tests and could thus, measure episodic memory. Furthermore, the results indicated 
Table 27 
The Best Mixed Predictor Model of MCI to AD Conversion in Year Two of ADNI2 
B = Regression coefficient used to calculate Exp(B) 
Exp(B) = predictive odds ratio 
S.E. = Standard Error 
 
Table 28 
The Accuracy and Accounted Variance of the Best Mixed Model in Year Two of ADNI2 
C&S R2 = Cox & Snell R-squared  




that individual episodic-memory measures were the best predictors of MCI to AD 
conversion. Comparatively, Individual neuroimaging markers could not predict MCI to AD 
conversion above chance averages and performed worse than episodic-memory measures. 
Mixed neuroimaging and episodic-memory models improved over time with these mixed 
models performing relatively worse or the same as mixed episodic-memory models or 





Chapter Four: Discussion and Conclusion 
 
4.1 Interpretation of Results 
The exponential increase in AD patients over the next 30 years is expected to create a 
global epidemic. Stronger treatment and diagnostic methods are required to actively combat 
AD; however, current measures cannot detect the disease at a significantly treatable or 
reversible stage. Accordingly, there is a critical need for early-stage AD detection methods. 
The present study sought to investigate the ability of episodic-memory measures to predict 
early-stage AD. Episodic-memory tests were used as they can specifically target the initial 
cognitive symptoms of AD during the early stages of the disease. Specifically, this study 
sought to predict MCI to AD conversion using multiple episodic-memory tests. The episodic-
memory models were also compared to common neuroimaging measures of AD to find the 
best predictor of MCI to AD conversion and thus early-stage AD. While other studies have 
examined episodic memory as a predictor of MCI to AD conversion, this is the first to 
incorporate all the episodic-memory measures from ADNI and properly evaluate and 
compare these measures to common neuroimaging predictors of AD. 
The results of this study are discussed in reference to the project research questions 
which are the following: Can general cognitive assessment tests used for AD, such as the 
MMSE and ADAS-Cog, be used to measure episodic memory? Which episodic-memory test 
best predicts MCI to AD conversion, and can mixed episodic-memory models predict 
conversion better than individual tests? Can individual neuroimaging measures predict MCI 
to AD conversion better than episodic-memory variables, and can a mixed model 




4.1.1 Construct Validity in Episodic-Memory Tests 
Before assessing the predictive ability of episodic-memory tests, we determined 
whether general multi-domain tests—namely, the MMSE and ADAS-cog—could be used to 
measure episodic memory. This was, in part, because prior research had suggested that these 
general diagnostic tests could measure episodic memory and because these tests were part of 
the ADNI composite memory score that we used to measure episodic memory (Crane et al., 
2012). Theoretically, it is not difficult to infer that the MMSE and ADAS-cog can measure 
episodic memory, as both tests involve recall tasks similar to the RAVLT. Accordingly, we 
consistently found, in all four years of ADNI2, that the general diagnostic tests and specific 
episodic-memory tests measured the same construct. This means that, to a degree, the MMSE 
and ADAS-cog can be used to measure episodic memory. While these results should not 
justify the use of the MMSE or ADAS-cog over specific tests such as the RAVLT for the 
study of episodic memory, it does clarify that these general tests can measure episodic 
memory and are justified for use in our study. Moreover, this means that, in research and 
clinical practice, specific delayed recall sections of general tests can be used as measures of 
episodic memory (e.g., ADASQ4). 
During the principle component analysis, the RAVLT Forgetting and RAVLT 
Percentage Forgetting were consistently in their own factor loading group. We theorised that 
the RAVLT forgetting group occurred because both measures are two quantifications of the 
same base statistic. Moreover, the second factor was not important, as the analysis was only 
concerned with general diagnostic tests and not with the relationship between RAVLT 
forgetting measures. In the third year of the ADNI2 cohort, there was more of a divide 
between general cognitive assessment tests and episodic-memory tests; however, overall, 
these two groups of tests were still related and could both measure episodic memory in MCI 
converters. The split between factors in the third year may be caused by the progression of 
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AD, as general multi-domain tests are often better later on during the progression of the 
disease, thus causing more of a split between types of tests. However, the disparity between 
specific and general tests reduced in the fourth year, and thus the third-year results, may also 
have just been an anomaly.  
4.1.2 Episodic-Memory Predictive Models 
The prime focus of this project was to evaluate the ability of episodic-memory tests to 
predict MCI to AD conversion both individually and in a battery. Across the first four years 
of ADNI2, all episodic-memory tests could predict MCI, with the exception on the RAVLT 
Forgetting variable. The predictive accuracy of individual episodic-memory tests also 
improved with time across the four years of ADNI2. The best episodic-memory tests 
predictive of MCI to AD conversion observed across all four years of ADNI2 were the LMT, 
the ADASQ4, the ADAS13, the ADNIMEM and the RAVLT Percent Forgetting. The 
following individual episodic-memory measures were the best predictors: ANIMEM in the 
first year (56.4%), the RAVLT Percent Forgetting in the second year (71.7%) and the LMT in 
the third (76.9%) and fourth years (77.2%). It is important to note that the RAVLT Percent 
Forgetting and LMT predicted MCI to AD conversion with a higher accuracy (63.8% and 
60.6%) in the first year of ADNI2; however, the results of these tests had to be omitted, as 
they violated the assumptions of a logistic regression (specifically the assumption of linearity 
of the logit). 
It was interesting to find that, unlike other general tests, the ADAS 13 had a good 
predictive ability similar to specific episodic-memory tests such as the LMT. Conversely, the 
MMSE was one of the worst predictors of MCI to AD conversion along with the RAVLT 
forgetting, the RAVLT immediate and the RAVLT learning measures. The results indicate 
that the MMSE is a poor predictor of MCI to AD conversion, which is consistent with 
findings in the literature (Arevalo-Rodriguez et al., 2015). The RAVLT forgetting measure 
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consistently could not predict MCI to AD conversion across all of the years of ADNI2. In the 
literature, this measure is often rated as one of the best episodic-memory measures of disease 
conversion. It is unknown whether prior studies have confused the RAVLT forgetting and 
RAVLT percentage forgetting measures or if our results are anomalous. Equally, our results 
have shown that the RAVLT forgetting measure can strongly predict MCI stability, so there 
might be some confusion with this statistic in the literature. Accordingly, the RAVLT 
Percentage Forgetting measure has also been found to be a strong predictor of AD in the 
literature (Moradi et al., 2017). It is important to note that the variability in RAVLT measures 
reinforce the notion that both clinicians and researchers should not use just the RAVLT to 
measure episodic memory. 
When assessing the predictive ability of mixed episodic-memory predictor models, it 
was found that all mixed models performed similarly or worse than individual predictor tests. 
Moreover, in the second and fourth years of ADNI2, mixed episodic-memory predictive 
models could not be formulated due to assumption violations. In the first year of ADNI2, the 
best mixed episodic-memory predictor model contained the RAVLT Immediate and the 
ADAS Q4 (53.1%) and was worse than the ADNIMEM measure alone (56.4%). The 
predictive accuracy of this model did not justify the use of multiple tests in the assessment of 
episodic-memory decline and MCI to AD conversion. Conversely, in the third year of 
ADNI2, the best mixed predictor model (accuracy of 77.7%) contained the ADNIMEM, the 
LMT and the ADASQ4 measures, and it predicted disease conversion better than individual 
episodic-memory measures. However, the best individual predictor in the third year had an 
accuracy of 76.9%; thus, an increase in accuracy of 1.2% does not logistically justify the use 
of two extra tests. Even the specially created ADNI composite memory score was often 
superseded by individual episodic-memory tests. These results are in contrast to those found 
by Chapman et al. (2011), who suggested that cognitive batteries could predict MCI to AD 
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conversion better than individual episodic-memory tests. Our results align more with De 
Simone et al. (2019), who found that individual and mixed measure episodic-memory models 
are both equally viable and tend to have similar accuracies.  
Statistically speaking, mixed episodic-memory predictive models can potentially 
provide small advantages in accuracy over individual episodic-memory models; however, 
clinically speaking, the logistical complexity gained through multiple tests is not worth the 
small increase in accuracy. In the case of this study, it is safe to say that more predictors and 
measures do not result in better models of MCI to AD conversion. Moreover, no mixed 
episodic-memory predictor models could be computed for the second and fourth years of the 
ADNI2 cohort, as all significant models violated the assumptions of linearity and 
multicollinearity, thus suggesting that model complexity can often diminish statistical power. 
We theorised that the assumption violations occurred because many of the episodic-memory 
measures share similar parent tests (e.g., ADAS 11, ADAS 13, ADASQ4) or because they all 
sought to measure episodic memory similarly (e.g., using list learning tasks). 
In conclusion, individual episodic-memory tests were found to be the best predictors 
of MCI to AD conversion in Research Question 2. We also found that episodic-memory 
predictive models generally improved across the years of ADNI2. At the beginning of 
ADNI2, the most accurate episodic-memory tests performed just above chance. Moreover, 
the best predictive model was the LMT in the fourth year of ADNI2. The results also 
indicated that specific episodic-memory tests consistently outperformed general multidomain 
tests, with only the ADAS 11 and 13 consistently rivalling specific episodic-memory tests. 
We theorise that the ADAS-cog performed well as an episodic-memory test, as it includes a 
delayed recall task. Finally, the RAVLT generally performed poorly with only the RAVLT 




4.1.3 Mixed model Predictors of Alzheimer’s Disease 
ADNI research commonly combines various cognitive, neuroimaging and biomarker 
measures together in models used to predict early-stage AD and MCI to AD conversion. For 
this reason, we wanted to utilise the biomarker and neuroimaging measures contained in the 
ADNI database to see if we could improve our episodic-memory predictive models. 
Unfortunately, we could not use any biomarker measures (e.g., Tau and Aβ), as these markers 
had severe amounts of missing data; however, this was not too discouraging, as biomarkers 
often perform poorly when predicting MCI to AD conversion as discussed in Section 1.3.3 
above (p. 8). Similarly, neuroimaging markers contained a decent amount of missing data in 
the third and fourth years of ADNI2; however, in this circumstance, we were able to study the 
markers in the first two years of ADNI2. 
Accordingly, in the first and second years of ADNI2, individual neuroimaging 
markers poorly predicted MCI to AD conversion in comparison to episodic-memory 
measures. In the first year, the best predictors of conversion were MRI atrophy measures of 
participants entorhinal (27.9%) and hippocampal (27.3%) regions. Similarly, in the second 
year, the entorhinal (43.4%) and hippocampal (42.4%) regions were the best neuroimaging 
predictors of MCI to AD conversion; however, these statistics were in no way good 
individual predictors of MCI to AD conversion. While we found that the entorhinal and 
hippocampal regions of the brain were the best neuroimaging predictors of disease 
conversion in concordance with the literature, our accuracy statistics were significantly 
weaker than those observed in other studies (Ihara et al., 2018; Moradi et al., 2017). We 
theorise that these weak results may have been obtained because neuroimaging measures 
improve with disease progression. As has been observed with the episodic-memory predictors 
mentioned above, neuroimaging measures may have improved in the third and fourth years of 
ADNI2; however, this cannot be confirmed due to the nature of our missing data. 
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Neuroimaging markers predicted MCI to AD conversion better when they were 
combined with episodic memory markers. Moreover, in both the first and second years of 
ADNI2, combined neuroimaging and episodic-memory mixed models predicted MCI to AD 
conversion the same as or better than all other models. In the first year, the ADAS11, LMT 
and UCSF entorhinal measures predicted disease conversion with an accuracy of 59.8%. In 
the second year, the ADAS13 and UCSF entorhinal measures predicted MCI to AD 
conversion with an accuracy of 70.5%. However, like the mixed episodic-memory models, 
these mixed models did not provide any significant increases in accuracy that would justify 
the use of multiple measures and MRI equipment over one single episodic-memory test. 
These results are similar to those obtained by Gomar et al. (2014), who found that adding 
neuroimaging measures to episodic-memory tests did not significantly improve predictive 
models. However, it would be interesting to see how episodic-memory models improved with 
neuroimaging measures in the later years of ADNI2, as there is a gradual increase in the 
accuracy of predictive measures observed in our data. 
In conclusion, our study has determined that, out of our variables, individual episodic-
memory measures such as the LMT are the best predictors of MCI to AD conversion and 
therefore of early-stage AD. While neuroimaging measures can increase the overall accuracy 
of predictive models, there is no advantage to using the technology when factoring in the 
logistical complexity and cost of the technology compared to the accessibility and accuracy 
of episodic-memory tests. Accordingly, when researching episodic memory in AD and MCI 
conversion, we recommend the use of the RAVLT Percent Forgetting, the ADASQ4 and the 
LMT for episodic-memory testing. It is also important to note that researchers need to be 
careful when using single episodic-memory measures, as they sometimes do not match the 
target population and perform differently at various stages of AD progression (e.g., tests 
performed with varying accuracies across ADNI2 in our study). Accordingly, we suggest that 
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multiple specific episodic-memory tests should be used to inform early-stage MCI to AD 
diagnosis. Furthermore, general multidomain tests should be added to inform diagnoses later 
on during AD progression. It is also imperative that multiple episodic-memory tests be 





4.2 Clinical and Theoretical Implications 
When concerning clinical research and practise, our study suggests that episodic-
memory tests are viable measures of MCI to AD conversion and, subsequently, of early-stage 
AD. These results indicate that clinicians could use specific episodic-memory tests such as 
the LMT to observe and diagnose early-stage AD. An increase in early-stage AD diagnoses 
through episodic-memory tests could consequentially enable researchers and clinicians to 
treat and observe the disease at a more manageable and reversible stage. This early detection 
ability may be the first step in combating the global epidemic of AD expected in the next 
three decades. Moreover, our study has shown that neuroimaging technology may not be 
necessary in early-stage AD diagnosis, as individual episodic-memory tests could predict the 
disease with the same or higher accuracy. This means that early-stage AD diagnoses and MCI 
to AD prediction methods can be relatively affordable and accessible due to the simplistic 
nature of pen-and-pencil tests.  
Furthermore, our study has confirmed that general multi-domain tests used in AD 
diagnosis (e.g., MMSE) are not strong predictors of early-stage MCI to AD conversion and 
thus should be used only when assessing mid to late-stage AD. However, our results have 
also indicated that multi domain tests that include delayed recall measures (e.g., ADAS13) 
may be more useful than other general tests (e.g., MMSE) in early-stage AD research. Our 
study has also found that all episodic memory and MRI predictors of disease conversion 
increase in accuracy over time. Accordingly, there is a need for clinicians to repeatedly 
observe tests over time to provide accurate diagnoses and avoid misdiagnosis. Moreover, 
using an incorrect test during the wrong stage of AD progression—such as using the MMSE 
in the early stages of MCI to AD conversion—will not provide accurate measures of AD. 
Generally, according to our results, we suggest the use of the LMT or ADAS Q4 when 
seeking to predict MCI to AD conversion. It is imperative that the correct test is used during 
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specific stages of the disease and, unfortunately, there is no consensus on which test is best 
suited for each stage of the disease or even how to determine which stage of AD an 
individual is in. 
Theoretical Implications 
As discussed in Section 1.2 (see p. 3), there is no clear theory of cognitive decline in 
AD. Moreover, theories of episodic memory function (see Section 1.4.1  p. 13) often do not 
discuss memory decline. Building on the component processing model of episodic memory, 
the amyloid cascade hypothesis, and our results, we theorise that episodic-memory decline in 
AD occurs due to a loss of connectivity in the MTL. Specifically, the component processing 
model states that the episodic-memory system formulates memories using a multitude of 
brain regions across the MLT and cortex. Accordingly, we theorize that episodic-memory 
decline in early-stage AD is derived from breakdowns in communication between brain 
regions relating to the aggregation of Aβ and tau pathology. We hypothesize that episodic-
memory decline relates to the disruption of neurons in line with the amyloid cascade 
hypothesis and is not a by-product of neurodegeneration. Specifically, episodic-memory 
declines because of communication breakdowns relating to tau and Aβ aggregation and not 
due to the loss of neurons in the MLT and cortex, which happens at a later stage. We theorise 
this because, in our population, episodic-memory decline was a significant predictor of MCI 
to AD conversion before neuroimaging predictors were. This led us to believe that the 
episodic memory system is interrupted before the progression of mass neurodegeneration. 
Like prior researchers, we also found that measures of the MLT such as hippocampal 
and entorhinal volume or atrophy are the best neuroimaging predictors of MCI to AD 
conversion. This agrees with the component processing model that regards the hippocampus 
and entorhinal cortex as pivotal to the aggregation and processing of episodic-memory 
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information. Conversely, we found that these predictors did not predict conversion with a 
high accuracy. For this reason, and due to our missing data, this topic requires further 




4.3 Review and Future Direction 
This study sought to predict disease conversion from MCI to AD as a way of 
detecting early-stage AD. Accordingly, we discovered that episodic-memory tests could be 
used to predict disease conversion with a moderate to strong accuracy. Thus, this study 
provides a unique outlook on early-stage AD prediction and has both strengths and 
limitations that should influence future research.   
4.3.1 Strengths 
This study excelled in its statistical analysis, theoretical background and population. 
First, the statistical analysis utilised both binary logistic regressions and multiple imputations 
which are not commonly used in this area of research; however, these statistical methods are 
highly revered in the statistical literature. A binary logistic regression gave us the unique 
opportunity to investigate a large number of variables at once while providing detailed 
analyses of each individual predictor of disease conversion. In the literature, it is common to 
use receiver operating characteristic curves to assess predictor accuracy and use linear 
regressions to formulate predictive models. By utilising a binary logistic regression, both the 
predictive accuracy and model construction can be performed at the same time while also 
obtaining detailed information on the odds ratios (increase or decrease in predictive ability) 
of individual variables. A binary logistic regression also fit our research questions and dataset 
best, as the analysis specialises in dichotomous categorical prediction (e.g., conversion and 
non-conversion) and secondary data (testing a model against observations). The multiple 
imputations also strengthened our dataset, as the corrections reduced the error rate and 
enabled us to correct missing data. Without the multiple imputations, this study would only 
have been able to consider episodic-memory variables and not neuroimaging measures. 
Another strength of this study can be found in its theoretic background. A key topic in 
this study was the lack of theoretical information explaining processes of episodic-memory 
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decline in AD; however, the existing theories gave us a strong background from which to 
consider how episodic memory is affected in AD. Specifically the amyloid cascade 
hypothesis in the component processing model of episodic memory provided enough 
information for us to consider and test a potential reason for episodic-memory decline in AD. 
Uniquely, the lack of theory surrounding episodic-memory decline in AD drove this study 
and enabled us to make a unique contribution to research. Furthermore, we were able to draw 
on research from multiple disciplines such as neuroscience, cognitive science and 
psychology. We believe that the incorporation of interdisciplinary knowledge was a strong 
foundation for this project and analysis.       
Lastly, the study population and, accordingly, the data acquired from the Alzheimer’s 
Disease Neuroimaging Initiative was pivotal to the success of this project. As previously 
mentioned, without the ADNI database, this project would not be able to longitudinally study 
early-stage AD or research so many participant and variables. Accordingly, the large 
population and the multitude of variables contained in the ADNI database statistically and 
theoretically strengthened this study. Specifically, the large number of MCI participants 
enabled us to use a binary logistic regression and perform a detailed analysis of each of the 
first four years of ADNI2. Moreover, the multitude of cognitive tests enabled us to 
investigate the differences between general tests for AD diagnosis (e.g., MMSE) and specific 
episodic-memory tests (e.g., RAVLT). This was important, as cognitive tests are often 
avoided in early-stage AD research because of the poor accuracy of general tests for AD 
diagnosis, and specific episodic-memory tests are rarely compared or utilised to predict 







It is important to note that this study had some limitations that should be considered in 
future studies. Primarily, this study was limited by missing data, the tests used by ADNI and 
the ability to assess disease misdiagnosis.  
Missing data was the largest limitation of this study. We were unable to study 
biomarkers for two years of neuroimaging markers due to the amount of missing data in the 
ADNI database. Ultimately, missing data could not be avoided, as we did not collect any data 
ourselves and we utilised statistical methods to recover as much data as possible. 
Accordingly, this study can only comment on the predictive ability of episodic-memory tests 
in the first four years and on neuroimaging measures in the first two years of ADNI2. We 
would have liked to have commented on the performance of neuroimaging predictors in the 
later years of ADNI2 and AD, as this is a key area of interest in the literature. It is unknown 
whether patterns of participant drop out occur in other ADNI cohorts; however, participant 
drop out is common in AD research due to the vulnerable nature of neurological populations. 
Next, this study was limited by the variables and tests available to use from the ADNI 
database. Accordingly, we had to fit the variables given to us to our research questions and 
tests. Subsequently, statistical models had problems with multicollinearity due to the 
similarity of the tests selected by ADNI. However, ADNI is in no way to blame, as the tests 
used are widely recommended in the literature. Ultimately, problems of multicollinearity and 
the need for more tests are consequences of using data not specifically collected for this 
study. 
Lastly, this study was limited in its ability to assess misdiagnosis. In both research and 
clinical practice, general assessment tests used for AD such as the MMSE are often prone to 
misdiagnosing forms of dementia (e.g., diagnosing Lewy body dementia as AD). While this 
study used a control group of MCI stable participants to test against converting participants, it 
86 
 
would have been good to also test stable AD and healthy aging participants and those with 
various forms of dementia (e.g., vascular dementia). We could not do this because our dataset 
from ADNI did not contain all of these participant groups and because a binary logistic 
regression must have dichotomous groups. In the case of our study, it was more important to 
confirm that episodic-memory tests can predict conversion than test misdiagnosis; however, 
this is the next logical step for future research. 
4.3.3 Future Direction 
Both the results and limitations of this project should direct future research. 
Particularly, future research should build on the episodic-memory models contained in this 
study and seek to apply findings about such tests and predictors to clinical research.  
Future research should continue to explore more episodic-memory tests and compare 
them to current mainstream predictors such as MRI measures. Specifically, future research 
should expand the pool of episodic-memory tests used to predict MCI to AD conversion to 
determine whether any other specific test can predict disease conversion with a high 
accuracy. Equally, new episodic-memory measures should be selected from different tests 
with unique methodologies to avoid problems of multicollinearity, such as those which 
occurred in this study. While all tests should be evaluated, it is also important to note that 
tests that are clinically assessable and easily administrable should be preferred over complex 
batteries. Our study suggests that complex measures involving many tests, such as the 
ADNINMEM measure, provide no advantage over individual tests. It is also important to 
note that future research should seek to explore specific tests that target episodic memory 
over general multidomain tests and also explore the relationships between said tests. Our 
study suggests that one reason for the lack of confidence in cognitive tests during early-stage 
AD diagnosis may be because researchers prefer general tests over specific tests. 
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Furthermore, it is important that future research further investigates the predictive 
ability of neuroimaging methods in detecting early-stage AD and, subsequently, MCI 
conversion. With respect to our study, future research should longitudinally assess a 
multitude of neuroimaging measures of MCI to AD conversion. While a study evaluating 
many neuroimaging measures requires a large amount of time and money, this may be 
possible once the current ADNI3 cohort is completed. Future research should also seek to 
evaluate episodic-memory measures in the ADNI3 cohort to replicate and confirm this study. 
This is important, as ADNI3 includes new biomarker and neuroimaging measures, such as 





4.4 Concluding Remarks 
Overall, this study was both a successful study and a defining research experience that 
will affect the rest of my research career. The primary goal of this study was to determine 
whether episodic-memory tests could predict MCI to AD conversion and therefore detect 
early AD. Moreover, this study sought to find reasons for episodic-memory decline in AD. 
Academically, this project has greatly improved my writing, statistical and communicative 
skills. I have learnt countless lessons that have already started to define my academic career 
and work. Personally, this study has also influenced my understanding of myself and my 
work ethic. While this project is only approximately 100 pages to the reader, to me it is the 
culmination of two years of work and personal development. I am incredibly proud of where 
I am and the effort I have put into this project. I have learned the true meaning of stress and 
anxiety yet also patience, satisfaction and happiness. 
I hope that this project has a positive effect on the AD literature and will be part of a 
wider movement that seeks to improve the lives of those with neurodegenerative diseases. It 
is my wish that AD is cured in my lifetime and that projects like this one can assist in getting 
the research one step closer to that goal. I think it is incredibly important that we continue to 
research and invest in early-stage detection methods for AD and MCI and promote research 
that can be translated into clinical practice. Everyone can do their part to help individuals 








This study would like to acknowledge the Alzheimer’s Disease Neuroimaging Initiative for 
their data which was crucial to the success of this study. 
This study would also like to acknowledge funding received through the Australian 
Government Research Training Program and Western Sydney Universities Master of 
Research Scholarship. Without funding from the Australian Government or Western Sydney 
University this project would not have been possible.   






Abikoff, H., Alvir, J., Hong, G., Sukoff, R., Orazio, J., Solomon, S., & Saravay, S. (1987). Logical 
memory subtest of the wechsler memory scale: Age and education norms and alternate-form 
reliability of two scoring systems. Journal of Clinical and Experimental Neuropsychology, 
9(4), 435–448. https://doi.org/10.1080/01688638708405063 
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., … Phelps, C. H. 
(2011). The diagnosis of mild cognitive impairment due to Alzheimer’s disease: 
Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups 
on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia, 7(3), 270–279. 
https://doi.org/10.1016/j.jalz.2011.03.008 
Alzheimer’s Association. (2018). 2018 Alzheimer’s disease facts and figures. Alzheimer’s & 
Dementia, 14(3), 367–429. 
Alzheimer’s Disease International. (2019). Dementia Statistics. Retrieved April 5, 2019, from 
Alzheimer’s Disease International website: https://www.alz.co.uk/research/statistics 
Alzheimer’s Disease Neuroimaging Initiative. (2016). ADNI3 Protocol. Retrieved April 11, 2019, 
from http://adni.loni.usc.edu/wp-content/themes/freshnews-dev-
v2/documents/clinical/ADNI3_Protocol.pdf 
Alzheimer’s Disease Neuroimaging Initiative. (2017a). ADNI About. Retrieved December 11, 2019, 
from http://adni.loni.usc.edu/about/ 
Alzheimer’s Disease Neuroimaging Initiative. (2017b). ADNI Data Types. Retrieved December 11, 
2019, from http://adni.loni.usc.edu/data-samples/data-types/ 
Alzheimer’s Disease Neuroimaging Initiative. (2017c). ADNI MRI Tool. Retrieved December 11, 
2019, from http://adni.loni.usc.edu/methods/mri-tool/ 
Arevalo-Rodriguez, I., Smailagic, N., Roqué I Figuls, M., Ciapponi, A., Sanchez-Perez, E., 
Giannakou, A., … Cullum, S. (2015). Mini-Mental State Examination (MMSE) for the 
detection of Alzheimer’s disease and other dementias in people with mild cognitive 
impairment (MCI). The Cochrane Database of Systematic Reviews, (3), CD010783. 
https://doi.org/10.1002/14651858.CD010783.pub2 
Armstrong, R. A. (2013). What causes alzheimer’s disease? Folia Neuropathologica, 51(3), 169–
188. https://doi.org/10.5114/fn.2013.37702 
Athinoula A. Martinos Center for Biomedical Imaging. (2019). Free Surfer Wiki. Retrieved 
December 11, 2019, from https://surfer.nmr.mgh.harvard.edu/fswiki 
Australian Bureau of Statistics. (2017). Causes of death, Australia, 2016. Australian Bureau of 
Statistics Canberra. 
Bak, T. H., Rogers, T. T., Crawford, L. M., Hearn, V. C., Mathuranath, P. S., & Hodges, J. R. 
(2005). Cognitive bedside assessment in atypical parkinsonian syndromes. Journal of 
91 
 
Neurology, Neurosurgery & Psychiatry, 76(3), 420–422. 
https://doi.org/10.1136/jnnp.2003.029595 
Barker, G. R. I., Banks, P. J., Scott, H., Ralph, G. S., Mitrophanous, K. A., Wong, L.-F., … 
Warburton, E. C. (2017). Separate elements of episodic memory subserved by distinct 
hippocampal-prefrontal connections. Nature Neuroscience, 20(2), 242–250. 
https://doi.org/10.1038/nn.4472 
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982). The cholinergic hypothesis of geriatric 
memory dysfunction. Science, 217(4558), 408–414. https://doi.org/10.1126/science.7046051 
Bastin, C., & Salmon, E. (2014). Early neuropsychological detection of Alzheimer’s disease. 
European Journal of Clinical Nutrition, 68(11), 1192–1199. 
https://doi.org/10.1038/ejcn.2014.176 
Bloom, G. S. (2014). Amyloid-β and tau: The trigger and bullet in Alzheimer disease pathogenesis. 
JAMA Neurology, 71(4), 505–508. https://doi.org/10.1001/jamaneurol.2013.5847 
Brown, J. (2015). The use and misuse of short cognitive tests in the diagnosis of dementia. Journal 
of Neurology, Neurosurgery & Psychiatry, 86(6), 680–685. https://doi.org/10.1136/jnnp-
2014-309086 
Brueggen, K., Dyrba, M., Barkhof, F., Hausner, L., Filippi, M., Nestor, P. J., … Teipel, S. J. (2015). 
Basal Forebrain and Hippocampus as Predictors of Conversion to Alzheimer’s Disease in 
Patients with Mild Cognitive Impairment—A Multicenter DTI and Volumetry Study. Journal 
of Alzheimer’s Disease: JAD, 48(1), 197–204. https://doi.org/10.3233/JAD-150063 
Cai, S., Huang, L., Zou, J., Jing, L., Zhai, B., Ji, G., … Ren, A. (2015). Changes in Thalamic 
Connectivity in the Early and Late Stages of Amnestic Mild Cognitive Impairment: A 
Resting-State Functional Magnetic Resonance Study from ADNI. PLoS ONE, 10(2), 
e0115573. https://doi.org/10.1371/journal.pone.0115573 
Chapman, R. M., Mapstone, M., McCrary, J. W., Gardner, M. N., Porsteinsson, A., Sandoval, T. C., 
… Reilly, L. A. (2011). Predicting Conversion from Mild Cognitive Impairment to 
Alzheimer’s Disease Using Neuropsychological Tests and Multivariate Methods. Journal of 
Clinical and Experimental Neuropsychology, 33(2), 187–199. 
https://doi.org/10.1080/13803395.2010.499356 
Cheke, L. G., & Clayton, N. S. (2013). Do different tests of episodic memory produce consistent 
results in human adults? Learning & Memory (Cold Spring Harbor, N.Y.), 20(9), 491–498. 
https://doi.org/10.1101/lm.030502.113 
Cheke, L. G., & Clayton, N. S. (2015). The six blind men and the elephant: Are episodic memory 
tasks tests of different things or different tests of the same thing? Journal of Experimental 
Child Psychology, 137, 164–171. https://doi.org/10.1016/j.jecp.2015.03.006 
Chu, L. W. (2012). Alzheimer’s disease: Early diagnosis and treatment. Hong Kong Medical Journal 
= Xianggang Yi Xue Za Zhi, 18(3), 228–237. 
Craig, L. A., Hong, N. S., & McDonald, R. J. (2011). Revisiting the cholinergic hypothesis in the 




Crane, P. K., Carle, A., Gibbons, L. E., Insel, P., Mackin, R. S., Gross, A., … Mungas, D. (2012). 
Development and assessment of a composite score for memory in the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI). Brain Imaging and Behavior; Indianapolis, 6(4), 502–516. 
http://dx.doi.org.ezproxy.uws.edu.au/10.1007/s11682-012-9186-z 
Csukly, G., Sirály, E., Fodor, Z., Horváth, A., Salacz, P., Hidasi, Z., … Szabó, Á. (2016). The 
Differentiation of Amnestic Type MCI from the Non-Amnestic Types by Structural MRI. 
Frontiers in Aging Neuroscience, 8. https://doi.org/10.3389/fnagi.2016.00052 
Cui, Y., Liu, B., Luo, S., Zhen, X., Fan, M., Liu, T., … Alzheimer’s Disease Neuroimaging 
Initiative. (2011). Identification of conversion from mild cognitive impairment to 
Alzheimer’s disease using multivariate predictors. PloS One, 6(7), e21896. 
https://doi.org/10.1371/journal.pone.0021896 
Davatzikos, C., Bhatt, P., Shaw, L. M., Batmanghelich, K. N., & Trojanowski, J. Q. (2011). 
Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification. 
Neurobiology of Aging, 32(12), 2322.e19-27. 
https://doi.org/10.1016/j.neurobiolaging.2010.05.023 
Davidson, P. S. R., & Winocur, G. (2010). Aging and Cognition. In G. F. Koob, M. L. Moal, & R. F. 
Thompson (Eds.), Encyclopedia of Behavioral Neuroscience (pp. 20–26). 
https://doi.org/10.1016/B978-0-08-045396-5.00031-2 
De Simone, M. S., Perri, R., Fadda, L., Caltagirone, C., & Carlesimo, G. A. (2019). Predicting 
progression to Alzheimer’s disease in subjects with amnestic mild cognitive impairment 
using performance on recall and recognition tests. Journal of Neurology, 266(1), 102–111. 
https://doi.org/10.1007/s00415-018-9108-0 
Dementia Australia. (2018). Dementia Prevalence Estimates 2018-2058. Retrieved April 5, 2019, 
from https://www.dementia.org.au/statistics 
Edvardsson, D., Winblad, B., & Sandman, P. (2008). Person-centred care of people with severe 
Alzheimer’s disease: Current status and ways forward. The Lancet Neurology, 7(4), 362–367. 
https://doi.org/10.1016/S1474-4422(08)70063-2 
Eichenbaum, H. (2017). Prefrontal-hippocampal interactions in episodic memory. Nature Reviews. 
Neuroscience, 18(9), 547–558. https://doi.org/10.1038/nrn.2017.74 
El Haj, M., Antoine, P., Amouyel, P., Lambert, J.-C., Pasquier, F., & Kapogiannis, D. (2016). 
Apolipoprotein E (APOE) ε4 and episodic memory decline in Alzheimer’s disease: A review. 
Ageing Research Reviews, 27, 15–22. https://doi.org/10.1016/j.arr.2016.02.002 
El Haj, M., Antoine, P., Nandrino, J.-L., & Kapogiannis, D. (2016). Autobiographical memory 
decline in Alzheimer’s Disease. Ageing Research Reviews, 27, 15–22. 
https://doi.org/10.1016/j.arr.2016.02.002 
Ewers, M., Brendel, M., Rizk-Jackson, A., Rominger, A., Bartenstein, P., Schuff, N., … Alzheimer’s 
Disease Neuroimaging Initiative (ADNI). (2014). Reduced FDG-PET brain metabolism and 
executive function predict clinical progression in elderly healthy subjects. NeuroImage. 
Clinical, 4, 45–52. https://doi.org/10.1016/j.nicl.2013.10.018 
93 
 
Faul, F., Erdfelder, E., Buchner, A., & Lang, A.-G. (2009). Statistical power analyses using 
G*Power 3.1: Tests for correlation and regression analyses. Behavior Research Methods, 
41(4), 1149–1160. https://doi.org/10.3758/BRM.41.4.1149 
Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007). G*Power 3: A flexible statistical power 
analysis program for the social, behavioral, and biomedical sciences. Behavior Research 
Methods, 39(2), 175–191. https://doi.org/10.3758/BF03193146 
Ferman, T. J., Smith, G. E., Kantarci, K., Boeve, B. F., Pankratz, V. S., Dickson, D. W., … Petersen, 
R. C. (2013). Nonamnestic mild cognitive impairment progresses to dementia with Lewy 
bodies. Neurology, 81(23), 2032–2038. https://doi.org/10.1212/01.wnl.0000436942.55281.47 
Ferreira-Vieira, T. H., Guimaraes, I. M., Silva, F. R., & Ribeiro, F. M. (2016). Alzheimer’s Disease: 
Targeting the Cholinergic System. Current Neuropharmacology, 14(1), 101–115. 
https://doi.org/10.2174/1570159X13666150716165726 
Field, A. (2013). Discovering Statistics Using IBM SPSS Statistics. SAGE. 
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999). The cholinergic hypothesis of 
Alzheimer’s disease: A review of progress. Journal of Neurology, Neurosurgery & 
Psychiatry, 66(2), 137–147. https://doi.org/10.1136/jnnp.66.2.137 
Frisoni, G. B., Boccardi, M., Barkhof, F., Blennow, K., Cappa, S., Chiotis, K., … Winblad, B. 
(2017). Strategic roadmap for an early diagnosis of Alzheimer’s disease based on biomarkers. 
The Lancet. Neurology, 16(8), 661–676. https://doi.org/10.1016/S1474-4422(17)30159-X 
Goldman, J. G., Weis, H., Stebbins, G., Bernard, B., & Goetz, C. G. (2012). Clinical differences 
among mild cognitive impairment subtypes in Parkinson’s disease. Movement Disorders, 
27(9), 1129–1136. https://doi.org/10.1002/mds.25062 
Gomar, J. J., Bobes-Bascaran, M. T., Conejero-Goldberg, C., Davies, P., Goldberg, T. E., & 
Alzheimer’s Disease Neuroimaging Initiative. (2011). Utility of combinations of biomarkers, 
cognitive markers, and risk factors to predict conversion from mild cognitive impairment to 
Alzheimer disease in patients in the Alzheimer’s disease neuroimaging initiative. Archives of 
General Psychiatry, 68(9), 961–969. https://doi.org/10.1001/archgenpsychiatry.2011.96 
Gomar, J. J., Conejero-Goldberg, C., Davies, P., Goldberg, T. E., & Alzheimer’s Disease 
Neuroimaging Initiative. (2014). Extension and refinement of the predictive value of different 
classes of markers in ADNI: Four-year follow-up data. Alzheimer’s & Dementia: The Journal 
of the Alzheimer’s Association, 10(6), 704–712. https://doi.org/10.1016/j.jalz.2013.11.009 
Hot, P., Rauchs, G., Bertran, F., Denise, P., Desgranges, B., Clochon, P., & Eustache, F. (2011). 
Changes in sleep theta rhythm are related to episodic memory impairment in early 
Alzheimer’s disease. Biological Psychology, 87(3), 334–339. 
https://doi.org/10.1016/j.biopsycho.2011.04.002 
Humphreys, M. S., Smith, S., Pachana, N. A., Tehan, G., & Byrne, G. J. (2010). Measuring episodic 
memory: A novel approach with an indefinite number of alternative forms. Applied Cognitive 
Psychology, 24(8), 1080–1094. https://doi.org/10.1002/acp.1591 
Ihara, R., Iwata, A., Suzuki, K., Ikeuchi, T., Kuwano, R., & Iwatsubo, T. (2018). Clinical and 
cognitive characteristics of preclinical Alzheimer’s disease in the Japanese Alzheimer’s 
94 
 
Disease Neuroimaging Initiative cohort. Alzheimer’s & Dementia: Translational Research & 
Clinical Interventions, 4, 645–651. https://doi.org/10.1016/j.trci.2018.10.004 
Iqbal, K., Liu, F., Gong, C.-X., & Grundke-Iqbal, I. (2010). Tau in Alzheimer Disease and Related 
Tauopathies. Current Alzheimer Research, 7(8), 656–664. 
Jack, C. R., Albert, M., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carillo, M., … Phelps, 
C. H. (2011). Introduction to Revised Criteria for the Diagnosis of Alzheimer’s Disease: 
National Institute on Aging and the Alzheimer Association Workgroups. Alzheimer’s & 
Dementia : The Journal of the Alzheimer’s Association, 7(3), 257–262. 
https://doi.org/10.1016/j.jalz.2011.03.004 
Kalat, J. W. (2018). Biological psychology (13th edition.). Boston, MA, USA: Cengage. 
Kato, Y., Narumoto, J., Matsuoka, T., Okamura, A., Koumi, H., Kishikawa, Y., … Fukui, K. (2013). 
Diagnostic performance of a combination of Mini-Mental State Examination and Clock 
Drawing Test in detecting Alzheimer’s disease. Neuropsychiatric Disease and Treatment, 9, 
581–586. https://doi.org/10.2147/NDT.S42209 
Landau, S. M., Mintun, M. A., Joshi, A. D., Koeppe, R. A., Petersen, R. C., Aisen, P. S., … Jagust, 
W. J. (2012). Amyloid deposition, hypometabolism, and longitudinal cognitive decline. 
Annals of Neurology, 72(4), 578–586. https://doi.org/10.1002/ana.23650 
Larner, A. J. (2019). Evaluating cognitive screening instruments with the “likelihood to be diagnosed 
or misdiagnosed” measure. International Journal of Clinical Practice, 73(2), e13265. 
https://doi.org/10.1111/ijcp.13265 
Lin, F., Ren, P., Mapstone, M., Meyers, S. P., Porsteinsson, A., & Baran, T. M. (2017). The 
cingulate cortex of older adults with excellent memory capacity. Cortex, 86, 83–92. 
https://doi.org/10.1016/j.cortex.2016.11.009 
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013). Apolipoprotein E and Alzheimer disease: Risk, 
mechanisms and therapy. Nature Reviews Neurology, 9(2), 106–118. 
https://doi.org/10.1038/nrneurol.2012.263 
Manly, C. A., & Wells, R. S. (2015). Reporting the Use of Multiple Imputation for Missing Data in 
Higher Education Research. Research in Higher Education, 56(4), 397–409. 
https://doi.org/10.1007/s11162-014-9344-9 
Michaelson, D. M. (2014). APOE ε4: The most prevalent yet understudied risk factor for 
Alzheimer’s disease. Alzheimer’s & Dementia, 10(6), 861–868. 
https://doi.org/10.1016/j.jalz.2014.06.015 
Mitchell, A. J., & Shiri-Feshki, M. (2009). Rate of progression of mild cognitive impairment to 
dementia—Meta-analysis of 41 robust inception cohort studies. Acta Psychiatrica 
Scandinavica, 119(4), 252–265. https://doi.org/10.1111/j.1600-0447.2008.01326.x 
Moradi, E., Hallikainen, I., Hänninen, T., Tohka, J., & Alzheimer’s Disease Neuroimaging Initiative. 
(2017). Rey’s Auditory Verbal Learning Test scores can be predicted from whole brain MRI 




Mormino, E. C., Kluth, J. T., Madison, C. M., Rabinovici, G. D., Baker, S. L., Miller, B. L., … 
Jagust, W. J. (2009). Episodic memory loss is related to hippocampal-mediated β-amyloid 
deposition in elderly subjects. Brain, 132(5), 1310–1323. 
https://doi.org/10.1093/brain/awn320 
Moscovitch, M. (1992). Memory and Working-with-Memory: A Component Process Model Based 
on Modules and Central Systems. Journal of Cognitive Neuroscience, 4(3), 257–267. 
https://doi.org/10.1162/jocn.1992.4.3.257 
Moscovitch, Morris, Cabeza, R., Winocur, G., & Nadel, L. (2016). Episodic Memory and Beyond: 
The Hippocampus and Neocortex in Transformation. Annual Review of Psychology, 67, 105–
134. https://doi.org/10.1146/annurev-psych-113011-143733 
Murphy, M. P., & LeVine, H. (2010). Alzheimer’s Disease and the β-Amyloid Peptide. Journal of 
Alzheimer’s Disease : JAD, 19(1), 311. https://doi.org/10.3233/JAD-2010-1221 
Natelson Love, M., Clark, D. G., Cochran, J. N., Den Beste, K. A., Geldmacher, D. S., Benzinger, T. 
L., … Roberson, E. D. (2017). Clinical, imaging, pathological, and biochemical 
characterization of a novel presenilin 1 mutation (N135Y) causing Alzheimer’s disease. 
Neurobiology of Aging, 49, 216.e7-216.e13. 
https://doi.org/10.1016/j.neurobiolaging.2016.09.020 
Nathan, P. J., Abbott, R., Lim, Y. Y., Galluzzi, S., Marizzoni, M., Bagnoli, C., … Frisoni, G. B. 
(2016). PT593. CSF Beta-Amyloid and APOE E4 Related Decline in Episodic Memory over 
12 months measured using the CANTAB in individuals with amnestic MCI: Results from the 
European-ADNI study. International Journal of Neuropsychopharmacology, 19(Suppl_1), 
18–19. https://doi.org/10.1093/ijnp/pyw044.593 
Nyhus, E., & Curran, T. (2010). Functional Role of Gamma and Theta Oscillations in Episodic 
Memory. Neuroscience and Biobehavioral Reviews, 34(7), 1023–1035. 
https://doi.org/10.1016/j.neubiorev.2009.12.014 
Perry, R. J., Watson, P., & Hodges, J. R. (2000). The nature and staging of attention dysfunction in 
early (minimal and mild) Alzheimer’s disease: Relationship to episodic and semantic 
memory impairment. Neuropsychologia, 38(3), 252–271. https://doi.org/10.1016/S0028-
3932(99)00079-2 
Povova, J., Ambroz, P., Bar, M., Pavukova, V., Sery, O., Tomaskova, H., & Janout, V. (2012). 
Epidemiological of and risk factors for Alzheimer’s disease: A review. Biomedical Papers of 
the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 156(2), 108–114. 
https://doi.org/10.5507/bp.2012.055 
Ramanan, V. K., Kim, S., Holohan, K., Shen, L., Nho, K., Risacher, S. L., … for the Alzheimer’s 
Disease Neuroimaging Initiative (ADNI). (2012). Genome-wide pathway analysis of memory 
impairment in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort implicates 
gene candidates, canonical pathways, and networks. Brain Imaging and Behavior, 6(4), 634–
648. https://doi.org/10.1007/s11682-012-9196-x 
Reiman, E. M., Quiroz, Y. T., Fleisher, A. S., Chen, K., Velez-Pardo, C., Jimenez-Del-Rio, M., … 
Lopera, F. (2012). Brain imaging and fluid biomarker analysis in young adults at genetic risk 
for autosomal dominant Alzheimer’s disease in the presenilin 1 E280A kindred: A case-
96 
 
control study. The Lancet Neurology, 11(12), 1048–1056. https://doi.org/10.1016/S1474-
4422(12)70228-4 
Roberts, R., Geda, Y., Knopman, D., Cha, R., Pankratz, V., Boeve, B., … Rocca, W. (2008). The 
Mayo Clinic Study of Aging: Design and Sampling, Participation, Baseline Measures and 
Sample Characteristics. Neuroepidemiology, 30(1), 58–69. 
https://doi.org/10.1159/000115751 
Russo, María J., Campos, J., Vázquez, S., Sevlever, G., & Allegri, R. F. (2017). Adding Recognition 
Discriminability Index to the Delayed Recall Is Useful to Predict Conversion from Mild 
Cognitive Impairment to Alzheimer’s Disease in the Alzheimer’s Disease Neuroimaging 
Initiative. Frontiers in Aging Neuroscience, 9. https://doi.org/10.3389/fnagi.2017.00046 
Russo, María Julieta, Cohen, G., Chrem Mendez, P., Campos, J., Nahas, F. E., Surace, E. I., … 
Sevlever, G. (2016). Predicting episodic memory performance using different biomarkers: 
Results from Argentina-Alzheimer’s Disease Neuroimaging Initiative. Neuropsychiatric 
Disease and Treatment, 12, 2199–2206. https://doi.org/10.2147/NDT.S107051 
Seo, E. H., Choo, I. H., & Alzheimer’s Disease Neuroimaging Initiative. (2016). Amyloid-
independent functional neural correlates of episodic memory in amnestic mild cognitive 
impairment. European Journal of Nuclear Medicine and Molecular Imaging, 43(6), 1088–
1095. https://doi.org/10.1007/s00259-015-3261-9 
Sharma, N., & Singh, A. N. (2016). Exploring Biomarkers for Alzheimer’s Disease. Journal of 
Clinical and Diagnostic Research : JCDR, 10(7), KE01–KE06. 
https://doi.org/10.7860/JCDR/2016/18828.8166 
Sterne, J. A. C., White, I. R., Carlin, J. B., Spratt, M., Royston, P., Kenward, M. G., … Carpenter, J. 
R. (2009). Multiple imputation for missing data in epidemiological and clinical research: 
Potential and pitfalls. BMJ, 338, b2393. https://doi.org/10.1136/bmj.b2393 
Stites, S. D., Milne, R., & Karlawish, J. (2018). Advances in Alzheimer’s imaging are changing the 
experience of Alzheimer’s disease. Alzheimer’s & Dementia : Diagnosis, Assessment & 
Disease Monitoring, 10, 285–300. https://doi.org/10.1016/j.dadm.2018.02.006 
Swain, D. G., O’Brien, A. G., & Nightingale, P. G. (1999). Cognitive assessment in elderly patients 
admitted to hospital: The relationship between the Abbreviated Mental Test and the Mini-
Mental State Examination. Clinical Rehabilitation, 13(6), 503–508. 
https://doi.org/10.1191/026921599670895633 
Tan, C.-C., Yu, J.-T., Wang, H.-F., Tan, M.-S., Meng, X.-F., Wang, C., … Tan, L. (2014). Efficacy 
and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of 
Alzheimer’s Disease: A Systematic Review and Meta-Analysis. Journal of Alzheimer’s 
Disease, 41(2), 615–631. https://doi.org/10.3233/JAD-132690 
Tannenbaum, C., Paquette, A., Hilmer, S., Holroyd-Leduc, J., & Carnahan, R. (2012). A Systematic 
Review of Amnestic and Non-Amnestic Mild Cognitive Impairment Induced by 
Anticholinergic, Antihistamine, GABAergic and Opioid Drugs. Drugs & Aging, 29(8), 639–
658. https://doi.org/10.1007/BF03262280 
Tapiola, T., Pennanen, C., Tapiola, M., Tervo, S., Kivipelto, M., Hänninen, T., … Soininen, H. 
(2008). MRI of hippocampus and entorhinal cortex in mild cognitive impairment: A follow-
97 
 
up study. Neurobiology of Aging, 29(1), 31–38. 
https://doi.org/10.1016/j.neurobiolaging.2006.09.007 
Teipel, S. J., Grinberg, L. T., Hampel, H., & Heinsen, H. (2009). Cholinergic System Imaging in the 
Healthy Aging Process and Alzheimer Disease. Encyclopedia of Neuroscience, 857–868. 
https://doi.org/10.1016/B978-008045046-9.02041-6 
Terry, A. V., & Buccafusco, J. J. (2003). The Cholinergic Hypothesis of Age and Alzheimer’s 
Disease-Related Cognitive Deficits: Recent Challenges and Their Implications for Novel 
Drug Development. Journal of Pharmacology and Experimental Therapeutics, 306(3), 821–
827. https://doi.org/10.1124/jpet.102.041616 
Tulving, E. (1972). Episodic and semantic memory. In Organization of memory (pp. xiii, 423–xiii, 
423). Oxford, England: Academic Press. 
Tulving, E. (1985). Memory and consciousness. Canadian Psychology, 26(1), 1–12. 
https://doi.org/10.1037/h0080017 
Tulving, E. (2002). Episodic memory: From mind to brain. Annual Review of Psychology, 1–19. 
Retrieved from Academic OneFile. 
Uddin, M. S., Kabir, M. T., Al Mamun, A., Abdel-Daim, M. M., Barreto, G. E., & Ashraf, G. M. 
(2019). APOE and Alzheimer’s Disease: Evidence Mounts that Targeting APOE4 may 
Combat Alzheimer’s Pathogenesis. Molecular Neurobiology, 56(4), 2450–2465. 
https://doi.org/10.1007/s12035-018-1237-z 
Vakil, E., & Blachstein, H. (1993). Rey auditory-verbal learning test: Structure analysis. Journal of 
Clinical Psychology, 49(6), 883–890. https://doi.org/10.1002/1097-
4679(199311)49:6<883::AID-JCLP2270490616>3.0.CO;2-6 
Velayudhan, L., Proitsi, P., Westman, E., Muehlboeck, J.-S., Mecocci, P., Vellas, B., … dNeuroMed 
Consortium. (2013). Entorhinal cortex thickness predicts cognitive decline in Alzheimer’s 
disease. Journal of Alzheimer’s Disease: JAD, 33(3), 755–766. https://doi.org/10.3233/JAD-
2012-121408 
Vemuri, P., Wiste, H. J., Weigand, S. D., Shaw, L. M., Trojanowski, J. Q., Weiner, M. W., … 
Alzheimer’s Disease Neuroimaging Initiative. (2009). MRI and CSF biomarkers in normal, 
MCI, and AD subjects: Predicting future clinical change. Neurology, 73(4), 294–301. 
https://doi.org/10.1212/WNL.0b013e3181af79fb 
Watson, J. L., Ryan, L., Silverberg, N., Cahan, V., & Bernard, M. A. (2014). Obstacles And 
Opportunities In Alzheimer’s Clinical Trial Recruitment. Health Affairs (Project Hope), 
33(4), 574–579. https://doi.org/10.1377/hlthaff.2013.1314 
Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., & Kirschner, M. W. (1975). A protein factor 
essential for microtubule assembly. Proceedings of the National Academy of Sciences of the 
United States of America, 72(5), 1858–1862. 
Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990). Neurotrophic and neurotoxic effects of 




Yip, A. G., Brayne, C., Easton, D., & Rubinsztein, D. C. (2002). Apolipoprotein E4 is only a weak 
predictor of dementia and cognitive decline in the general population. Journal of Medical 
Genetics, 39(9), 639–643. 
 
